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ABSTRACT
Background
Neuropathic pain, which is due to nerve disease or damage, represents a significant burden on people and society. It can be particularly
unpleasant and achieving adequate symptom control can be difficult. Non-pharmacological methods of treatment are often employed
by people with neuropathic pain and may include transcutaneous electrical nerve stimulation (TENS). This review supersedes one
Cochrane Review ’Transcutaneous electrical nerve stimulation (TENS) for chronic pain’ (Nnoaham 2014) and one withdrawn protocol
’Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults’ (Claydon 2014). This review replaces the original
protocol for neuropathic pain that was withdrawn.
Objectives
To determine the analgesic effectiveness of TENS versus placebo (sham) TENS, TENS versus usual care, TENS versus no treatment
and TENS in addition to usual care versus usual care alone in the management of neuropathic pain in adults.
Search methods
We searched CENTRAL, MEDLINE, Embase, PsycINFO, AMED, CINAHL, Web of Science, PEDro, LILACS (up to September
2016) and various clinical trials registries. We also searched bibliographies of included studies for further relevant studies.
Selection criteria
We included randomised controlled trials where TENS was evaluated in the treatment of central or peripheral neuropathic pain. We
included studies if they investigated the following: TENS versus placebo (sham) TENS, TENS versus usual care, TENS versus no
treatment and TENS in addition to usual care versus usual care alone in the management of neuropathic pain in adults.
Data collection and analysis
Two review authors independently screened all database search results and identified papers requiring full-text assessment. Subsequently,
two review authors independently applied inclusion/exclusion criteria to these studies. The same review authors then independently
extracted data, assessed for risk of bias using the Cochrane standard tool and rated the quality of evidence using GRADE.
Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults (Review)
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Main results
We included 15 studies with 724 participants. We found a range of treatment protocols in terms of duration of care, TENS application
times and intensity of application. Briefly, duration of care ranged from four days through to three months. Similarly, we found variation
of TENS application times; from 15 minutes up to hourly sessions applied four times daily. We typically found intensity of TENS set
to comfortable perceptible tingling with very few studies titrating the dose to maintain this perception. Of the comparisons, we had
planned to explore, we were only able to undertake a quantitative synthesis for TENS versus sham TENS. Insufficient data and large
diversity in the control conditions prevented us from undertaking a quantitative synthesis for the remaining comparisons.
For TENS compared to sham TENS, five studies were suitable for pooled analysis. We described the remainder of the studies in
narrative form. Overall, we judged 11 studies at high risk of bias, and four at unclear risk. Due to the small number of eligible studies,
the high levels of risk of bias across the studies and small sample sizes, we rated the quality of the evidence as very low for the pooled
analysis and very low individual GRADE rating of outcomes from single studies. For the individual studies discussed in narrative form,
the methodological limitations, quality of reporting and heterogeneous nature of interventions compared did not allow for reliable
overall estimates of the effect of TENS.
Five studies (across various neuropathic conditions) were suitable for pooled analysis of TENS versus sham TENS investigating change
in pain intensity using a visual analogue scale. We found a mean postintervention difference in effect size favouring TENS of -1.58
(95% confidence interval (CI) -2.08 to -1.09, P < 0.00001, n = 207, six comparisons from five studies) (very low quality evidence).
There was no significant heterogeneity in this analysis. While this exceeded our prespecified minimally important difference for pain
outcomes, we assessed the quality of evidence as very low meaning we have very little confidence in this effect estimate and the true
effect is likely to be substantially different from that reported in this review. Only one study of these five investigated health related
quality of life as an outcome meaning we were unable to report on this outcome in this comparison. Similarly, we were unable to report
on global impression of change or changes in analgesic use in this pooled analysis.
Ten small studies compared TENS to some form of usual care. However, there was great diversity in what constituted usual care,
precluding pooling of data. Most of these studies found either no difference in pain outcomes between TENS versus other active
treatments or favoured the comparator intervention (very low quality evidence). We were unable to report on other primary and
secondary outcomes in these single trials (health-related quality of life, global impression of change and changes in analgesic use).
Of the 15 included studies, three reported adverse events which were minor and limited to ’skin irritation’ at or around the site of
electrode placement (very low quality evidence). Three studies reported no adverse events while the remainder did not report any detail
with regard adverse events.
Authors’ conclusions
In this review, we reported on the comparison between TENS and sham TENS. The quality of the evidence was very low meaning
we were unable to confidently state whether TENS is effective for pain control in people with neuropathic pain. The very low quality
of evidence means we have very limited confidence in the effect estimate reported; the true effect is likely to be substantially different.
We make recommendations with respect to future TENS study designs which may meaningfully reduce the uncertainty relating to the
effectiveness of this treatment modality.

PLAIN LANGUAGE SUMMARY
Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain
Bottom line
For adults with neuropathic pain, it is impossible to confidently state whether TENS is effective in relieving pain when compared to
sham TENS.
Background
Neuropathic pain is pain due to injury or disease to nerves and can be difficult to treat effectively. It may occur following direct nerve
injury or develop due to problems like diabetes, shingles and carpal tunnel syndrome. TENS is a common treatment for a range of
pain conditions. It involves using a small battery operated unit to apply low level electrical currents through electrodes attached to the
skin. This is suggested to relieve pain.
Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults (Review)
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Review question
Does TENS improve pain intensity and health related quality of life in adults with neuropathic pain?
Study characteristics
We reviewed all eligible clinical trials comparing TENS to ’fake’ TENS (known as ’sham’), usual care or no treatment, or comparing
TENS plus usual care versus usual care alone, for neuropathic pain in adults. As of September 2016, we found 15 studies eligible for
inclusion. Of these 15 studies, we were able to combine results from five studies to investigate the effect of TENS compared to sham
TENS for treatment of pain. The studies involved a range of neuropathic pain problems (e.g. people with spinal cord injury, back pain
with nerve involvement, complications associated with diabetes, etc.). We found the quality of the studies overall to be low.
Key findings
We were unable to confidently state whether TENS is effective in relieving pain compared to sham TENS in people with neuropathic
pain. This is due to the very low quality of the evidence, which means we have very limited confidence in this result and that future
studies are likely to change this result. Lack of reported data meant we were unable to draw any conclusion on the effect of TENS
treatment on health related quality of life, pain relieving medicine use or people’s impression of how TENS changed their condition.
We described the results of 10 further studies comparing TENS against other types of treatment. These 10 studies were quite varied
and so we could not combine them and analyse them together. This, together with the very low quality of these 10 studies, meant we
were unable to judge pain relief, health related quality of life, pain medication use or impression of change.
In three of the 15 studies, some people using TENS experienced skin irritation under the electrode pads. Three studies reported no
problems and the remaining studies did not provide any details on side effects. Based on this, it is not realistic to comment on side
effects associated with TENS use.

Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults (Review)
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]

TENS versus sham TENS for neuropathic pain in adults
Patient or population: adults with neuropathic pain
Settings: secondary care
Intervention/ comparison: TENS vs sham TENS
Outcome: changes in pain intensity (VAS)
Outcomes

Effect estimate
(95% CI)

No of participants
(studies)

Pain intensity changes
(VAS 0-10)

Favoured TENS. M ean 207 (5)
dif f erence
-1.58 (95% CI -2.08 to
-1.09)

Quality of the evidence Comments
(GRADE)
⊕

Very lowa

Downgraded 3 levels
due to m ultiple
sources of potential
bias, sm all num ber
and size of studies.

Changes in health re- No data
lated quality of lif e

-

-

-

Changes in participant No data
global im pression of
change

-

-

-

Change in analgesic Not estim able
m edication use

-

-

-

Incidence/ nature of ad- Not estim able
verse events

-

-

-

CI: conf idence interval; TENS: transcutaneous electrical nerve stim ulation; VAS: visual analogue scale.
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef f ect lies close to that of the estim ate of the ef f ect.
M oderate quality: we are m oderately conf ident in the ef f ect estim ate; the true ef f ect is likely to be close to the estim ate of
ef f ect, but there is a possibility that it is substantially dif f erent.
Low quality: our conf idence in the ef f ect estim ate is lim ited; the true ef f ect m ay be substantially dif f erent f rom the estim ate
of the ef f ect.
Very low quality: we have very little conf idence in the ef f ect estim ate; the true ef f ect is likely to be substantially dif f erent
f rom the estim ate of ef f ect
a Downgraded

twice f or lim itations of studies and once f or im precision.

Description of the condition
Neuropathic pain is defined as “pain caused by a lesion or disease
of the somatosensory system” and represents a significant source of
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chronic pain and loss of function at both an individual and societal
level (Jensen 2011). Approximately 20% of adults in the USA
and 27% in the EU report chronic pain (Kennedy 2014; Leadley
2012). Within this, it is estimated that 20% of people with chronic
pain will have neuropathic pain characteristics, translating to an
approximate prevalence of 6% to 7% in the general population
(Bouhassira 2008). This is confirmed by one systematic review
that estimated a population prevalence for neuropathic pain of
6.9% to 10% (van Hecke 2014). Neuropathic pain is often rated
as particularly intense and distressing and can have a significant
negative impact on activities of daily living and quality of life
(Leadley 2014; McDermott 2006; Moore 2014).
Neuropathic pain may be classified as peripheral or central in origin
depending on the site of lesion or disease. Peripheral neuropathic
pain results from injury or disease of the peripheral nerves and includes conditions such as post-traumatic nerve injury, diabetic peripheral neuropathy (or painful diabetic neuropathy (PDN)) and
postherpetic neuralgia (PHN). Central neuropathic pain results
from injury or disease affecting the central nervous system (spinal
cord, brainstem or brain) and includes central poststroke pain,
postspinal cord injury pain and pain related to multiple sclerosis.
Regardless of the causal condition or classification there are common features associated with neuropathic pain. Typically, neuropathic pain is associated with positive features such as spontaneous
pain, hyperalgesia (excessive pain to a painful stimulus) and allodynia (pain evoked by a normally non-painful stimulus), as well as
negative features such as sensory loss, weakness and hypoaesthesia (reduced sense of touch or sensation) (Baron 2010; Vranken
2012). For patients, this translates to pain being caused by innocuous stimuli such as light touch or gentle movement, increased pain
in response to noxious stimuli, and reduced sensory and motor
function (Baron 2010; Maier 2010; Vranken 2012). Additionally,
pain may be perceived in the absence of provoking stimuli (Baron
2010; Baron 2012).
The mechanisms underpinning this persistent pain state are complex. It is most likely that a mix of peripheral and central mechanisms are responsible for ongoing pain perception. Following a lesion or disease in a peripheral somatosensory structure (e.g. peripheral nerve), inflammatory mediators are released that causes sensitisation of nociceptors (nerve receptors that respond to tissue damaging stimuli or threat of damage) resulting in lowered stimulation
thresholds and enhanced activity in these receptors (Cohen 2014).
Damage to neural structures (at both peripheral nerve and central
nervous system levels) can result in longer term changes to their
structure and function (Black 2008; Levinson 2012), resulting in
abnormal or excessive activity in areas of damaged neural tissue
that is thought to lead to ongoing and often severe and intractable
pain (Cohen 2014). These changes may also be accompanied by
a decreased capacity of the body’s natural pain modulation mechanisms (known as endogenous analgesia), further compounding
the pain perceived (Baron 2010). These multiple, integrated pain
mechanisms result in neuropathic pain being particularly difficult

to treat and ongoing pain with limited response to treatment is
common. First line management of neuropathic pain is primarily
pharmacological (Dworkin 2013; O’Connor 2009); however, it
is also common for management to include non-pharmacological
treatments such as psychological or physical interventions including transcutaneous electrical nerve stimulation (TENS). Standard
TENS units are portable, widely available, easily self-administered
and are a popular adjunct therapy for people with chronic neuropathic pain (Johnson 2011).

Description of the intervention
TENS is the therapeutic application of transcutaneous (over the
skin) electrical stimulation and is primarily used for pain control in
a wide range of acute and chronic pain conditions (APTA 2001).
TENS units typically use adhesive electrodes applied to the skin
surface to apply pulsed electrical stimulation that can be modified
in terms of frequency (stimulation rate), intensity and duration (
Johnson 2011). TENS application is commonly described as being
in either high or low frequency modes. Low frequency TENS
is consistently defined as being 10 Hz or less (Bjordal 2003;
Moran 2011; Sabino 2008), while high frequency TENS typically
appears to be described as ranging up to 50 Hz or 100 Hz and
above (Moran 2011; Santos 2013; Sluka 2003; Sluka 2005). Low
frequency TENS is often used at higher intensities eliciting motor
contraction, while high frequency TENS has traditionally been
used at lower intensities (Walsh 2009). Modulated TENS applies
stimulation across a range of frequencies and may help ameliorate
development of tolerance to TENS (Sluka 2013).
Intensity appears to be a critical factor in optimising TENS efficacy and increasingly it is thought that regardless of frequency of
application, the intensity needs to produce a strong, non-painful
sensation that ideally is titrated during treatment to maintain the
intensity level (Bjordal 2003; Moran 2011; Sluka 2013). To account for the suggested importance of this, it was proposed that
this review would undertake a subgroup analysis based on intensity: strong and titrated versus all other application of intensities.
Placement of electrodes may influence response, although this issue is somewhat ambiguous with local, related spinal segment and
contralateral electrode placement demonstrating an effect in both
animal and human studies (Brown 2007; Chesterton 2003; Dailey
2013; Sabino 2008; Somers 2009). Timing of outcome measurement requires consideration when analysing TENS studies as theory predicts that the TENS analgesia induced should peak during
or immediately after use (Sluka 2013).

How the intervention might work
TENS induced analgesia is thought to be multifactorial and encompasses likely peripheral, spinal and supraspinal mechanisms.
In one animal study, the increased mechanical sensitivity caused
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by peripheral injection of serotonin (a substance naturally produced following injury/inflammation) was decreased by application of TENS (Santos 2013). Importantly, it was demonstrated
that this analgesia was partly mediated by peripheral mechanisms
as preinjection of a peripheral opioid receptor blocker decreased
the analgesia produced, implying the TENS effect was mediated
via activation of these peripheral receptors (Santos 2013). A spinal
effect for electrical stimulation was initially demonstrated by Wall
1967, and was suggested to work via the ’pain-gate’ mechanism
proposed in 1965 (Melzack 1965). The pain gate theory proposes
that large diameter (Aβ) afferent fibres (carrying sensations such
as vibration, touch, etc.) inhibit nociceptive activity in the dorsal horn of the spinal cord, with a resultant decrease in pain perception (Melzack 1965). TENS application and its stimulation
of peripheral neural structures is a source of considerable large
diameter afferent activity and this is therefore a plausible means
of TENS induced analgesia. TENS is also thought to have additional spinal segmental effects; decreased inflammation-induced
dorsal horn neuron sensitisation (Sabino 2008), altered levels of
neurotransmitters such as gamma-aminobutyric acid (GABA) and
glycine, which are thought to be involved in inhibition of nociceptive traffic (Maeda 2007; Somers 2009), and modulation of the
activity of the cells that provide support/surround neurons (glial
cells) in the spinal cord (Matsuo 2014), have all been suggested
as means by which TENS may produce analgesia at a spinal segmental level.
Further, it appears that TENS may have an effect on endogenous analgesia. Descending activity relayed via the midbrain periaqueductal grey (PAG) and the rostral ventral medulla (RVM) in
the brainstem may have inhibitory effects at the segmental level
(Gebhart 2004). This PAG-RVM relayed segmental inhibition is
mediated in part via opioidergic pathways (Calvino 2006; Gebhart
2004). TENS induced analgesia has been shown to be reversible
with preinjection of opioid receptor blockers in both the PAG and
RVM in rats with experimentally induced peripheral inflammation implying that this may be an operational pathway by which
TENS contributes to analgesia (DeSantana 2009; Kalra 2001).
This descending mechanism may also exist in humans with pain.
An enhanced conditioned pain modulation (descending modulation) response has been observed in people with fibromyalgia during active TENS application compared to no TENS or placebo
TENS (Dailey 2013). The descending modulation of pain is apparently not related to frequency of TENS stimulation employed
(DeSantana 2009), rather it is the intensity of stimulation that appears to be critical in TENS analgesia (Moran 2011; Sluka 2013).
Low frequency and high frequency TENS effects have been shown
to be mediated via µ- and δ-opioid receptor classes, respectively,
and as such low frequency TENS effects may be limited in people
using opioids for pain relief as they primarily act via µ-opioid
receptor pathways (Leonard 2010; Leonard 2011; Sluka 2013).
Given that pharmacological management of neuropathic pain may
involve opioid medication, it is possible this may impact upon

low frequency TENS efficacy if used concurrently. Therefore, this
review proposes a subgroup analysis of low versus high frequency
TENS application to investigate this further.
These descending inhibitory mechanisms have also been implicated in placebo analgesia (the phenomena of improvements in
pain that follow the delivery of an inert treatment) (Eippert 2009);
therefore, it is possible that the suggested mechanisms of TENS
induced analgesia described above may not necessarily represent
specific effects of electrical stimulation but could possibly result
purely from the therapeutic ritual of providing a TENS unit.

Sham credibility issues in studies of
transcutaneous electrical nerve stimulation
One issue regarding the credibility of sham conditions specifically
for TENS studies is whether the sham condition that is employed
controls adequately for all aspects of the treatment experience.
Various types of sham TENS have been proposed including deactivated units that are identical in appearance but deliver no actual
stimulation to devices where an initial brief period of stimulation
at the start of use is delivered and then faded out (Rakel 2010).
To try to enhance blinding in these paradigms, the information
given to participants is often limited regarding what they should
feel when the device is switched on. However, it is clear that there
are substantial threats to the credibility of these shams when compared to active stimulation that elicits strong sensations. Given
that the effectiveness of TENS is widely thought to be related to
the intensity of the stimulus, a true sham that establishes robust
blinding of participants is not achievable (Sluka 2013). This represents a risk of bias to all sham controlled trials of TENS.

Why it is important to do this review
TENS is a widely used and readily available adjunct therapy for
people with chronic pain and has the benefit of having an apparently low risk profile. This review supersedes one Cochrane
Review: ’Transcutaneous electrical nerve stimulation (TENS) for
chronic pain’ (Nnoaham 2014 (withdrawn)); and one withdrawn
protocol ’Transcutaneous electrical nerve stimulation (TENS) for
neuropathic pain in adults’ (Claydon 2014 (withdrawn)). The
original review for chronic pain was split into two titles, one on
neuropathic pain and one on fibromyalgia (Johnson 2016). This
review replaces the original protocol for neuropathic pain that was
withdrawn. There are a number of systematic reviews of the effect of TENS across various painful conditions (e.g. labour pain,
rheumatoid arthritis, phantom limb pain and chronic low back
pain) (Brosseau 2003; Khadilkar 2008; Dowswell 2009; Johnson
2010; Johnson 2015). There are no consistent findings and most
reviews comment on the lack of good quality trials and consequent
difficulty in estimating effect sizes. However, there is no previous
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Cochrane Review examining the effect of TENS on neuropathic
pain.

considered in separate Cochrane Reviews (Johnson 2016; Smart
2016).
Types of interventions

OBJECTIVES
To determine the analgesic effectiveness of TENS versus placebo
(sham) TENS, TENS versus usual care, TENS versus no treatment
and TENS in addition to usual care versus usual care alone in the
management of neuropathic pain in adults.

METHODS

Criteria for considering studies for this review

Types of studies
We included randomised controlled trials (RCTs) or quasi-randomised trials (including cross-over designs) of TENS applied as
treatment for central or peripheral neuropathic pain of any aetiology in adults. We excluded non-randomised studies, case reports/series, studies of experimental pain, clinical observations and
systematic reviews. We assessed studies for inclusion regardless of
their publication status. We excluded studies designed to test the
immediate effects of a single treatment only with follow-up less
than 24 hours. For non-English language papers, we sourced translators through Cochrane Pain, Palliative and Supportive Care Review Group as well as personal networks where available.

Types of participants
We included participants aged 18 years or over identified as having pain of neuropathic origin from a wide range of conditions,
including, but not limited to:
• cancer-related neuropathy;
• HIV neuropathy;
• painful diabetic neuropathy (PDN);
• phantom limb pain;
• postherpetic neuralgia (PHN);
• postoperative or traumatic neuropathic pain;
• spinal cord injury;
• poststroke pain;
• trigeminal neuralgia.
We excluded studies that included participants with a mix of neuropathic and non-neuropathic pain where it was impossible to extract data for the neuropathic pain participants independently. We
excluded studies that included participants with complex regional
pain syndrome (Type I or II) or fibromyalgia as these studies are

We included all standard modes of TENS, regardless of the device
manufacturer, in which the TENS condition delivered a clearly
perceptible sensation. Given that self-use and portability are key
clinical features of TENS, we excluded non-portable electrical
stimulation devices such as interferential therapy (IFT). We included any parameters of treatment that evoked a perceptible sensation, and any frequency or duration of treatment or surface electrode configuration. We excluded studies delivering intensities of
TENS that were subperceptual or barely perceptual due to the
risk of suboptimal treatment. We excluded studies where current
was delivered percutaneously (e.g. electroacupuncture, percutaneous electrical nerve stimulation (PENS), neuroreflexotherapy)
and where the effect of TENS could not be separated from the effects of other treatments (i.e. comparison interventions standardised between groups). The comparisons of interest were TENS
versus placebo (sham) TENS, TENS versus usual care, TENS versus no treatment and TENS in addition to usual care versus usual
care alone.
Types of outcome measures
We included studies with pain intensity as the primary or secondary outcome.
Primary outcomes

• Changes in pain intensity as measured using a visual
analogue scale (VAS), numerical rating scale (NRS), verbal rating
scale or Likert scale.
• Changes in health related quality of life (HRQoL) using
any validated tool (e.g. 36-item Short Form (SF-36), six-item
Short Form (SF-6), EuroQol).
Secondary outcomes

• Changes in participant global impression of change (PGIC)
scales.
• Change in analgesic medication use.
• Incidence/nature of adverse events.

Search methods for identification of studies

Electronic searches
We searched the following electronic databases using a combination of controlled vocabulary, medical subject headings (MeSH)
and free-text terms to identify published articles.
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• Cochrane Central Register of Controlled Trials
(CENTRAL; 2016 Issue 8) via CRSO;
• MEDLINE (via Ovid) 1946 to August week 5 2016;
• Embase (via Ovid) 1974 to 2016 week 37;
• CINAHL (EBSCO) 1982 to August 2016;
• PsycINFO (Ovid) 1806 to July week 4 2016;
• LILACS (Birme) 1985 to September 2016;
• PEDro June 2016;
• Web of Science (ISI) SCI, SSCI, CPCI-S, CPCI-SS to
September 2016;
• AMED (via Ovid) 1985 to August 2016;
• Database of Abstracts of Reviews of Effects June 2016;
• Health Technology Assessments February 2017.

There were no language restrictions. The search strategies used can
be found in Appendix 1.

Searching other resources
We
searched
the metaRegister of controlled trials (mRCT) (www.controlledtrials.com/mrct), ClinicalTrials.gov (www.clinicaltrials.gov), and
the World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/) for
ongoing trials. In addition, we checked the reference lists of reviews and retrieved articles for additional studies. We also sought
relevant expert input in an attempt to elicit further contribution
regarding novel studies.

Unpublished data

To minimise the prospect of publication bias, we undertook a
further search of the following:
• OpenGrey (System for Information on Grey Literature in
Europe);
• Dissertation abstracts (ProQuest);
• National Research Register Archive;
• Health Services Research Projects in Progress;
• Pan African Clinical Trials Registry;
• EU Clinical Trials Register.

Data collection and analysis

Selection of studies
Two review authors (WG and BMW) independently assessed the
titles and abstracts of potential studies identified by the search
strategy for their eligibility. If the eligibility of a study was unclear
from the title and abstract, we assessed the full paper. We excluded
studies that did not match the inclusion criteria (see Criteria for
considering studies for this review). We resolved disagreements
between review authors regarding a study’s inclusion by discussion.
A third review author (NEO) was available to assess relevant studies
if resolution and agreement could not be reached. This option was
not required. We did not anonymise studies prior to assessment.
A PRISMA study flow diagram documents the screening process
(Figure 1) (Liberati 2009), as recommended in Part 2, Section
11.2.1 of the Cochrane Handbook for Systematic Reviews of Interventions (Schünemann 2011).
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Figure 1. Study flow diagram.
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Data extraction and management
Two review authors (WG and BMW) independently extracted
data from all included studies using a standardised, piloted data
extraction form. We resolved any discrepancies/disagreement by
consensus. A third review author (NEO) was available for arbitration if consensus was not achieved. This option was not required.
We extracted the following data from each study included in the
review:
• country of origin;
• study design;
• study population (including diagnosis, diagnostic criteria
used, symptom duration, age, gender);
• concomitant treatments that may affect outcome
(medication, procedures, etc.);
• sample size, active and control/comparator groups;
• intervention(s) (including type, parameters (e.g. frequency,
intensity, duration, electrode position, setting and professional
discipline of the clinician delivering the therapy);
• type of placebo/comparator intervention;
• outcomes (primary and secondary) and time points assessed
(only for the comparisons of interest to this review);
• adverse events;
• industry sponsorship;
• author conflict of interest statements.

Assessment of risk of bias in included studies
Two review authors (WG and BMW) independently assessed risk
of bias for each study, using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions and adapted from
those used by the Cochrane Pregnancy and Childbirth Group,
with any disagreements resolved by discussion (Higgins 2011).
In cases where consensus was not reached, a third review author
(NEO) was available for arbitration. This option was not required.
For each study of parallel design, we assessed the following.
• Random sequence generation (selection bias). We assessed
the method used to generate allocation sequence as:
◦ low risk of bias (any truly random process, e.g.
random number table; computer random number generator);
◦ unclear risk of bias (method used to generate sequence
not clearly stated);
◦ high risk of bias (studies using a non-random process,
e.g. odd or even date of birth; hospital or clinic record number).
• Allocation concealment (checking for possible selection
bias). We assessed the method used to conceal allocation to
group assignment as:
◦ low risk of bias (e.g. telephone or central
randomisation; consecutively numbered sealed opaque

envelopes);
◦ unclear risk of bias (method not clearly stated);
◦ high risk of bias (studies that did not conceal
allocation e.g. open list).
• Blinding of study participants (checking for possible
performance and detection bias). We assessed the methods used
to blind participants and personnel (care providers) as follows:
◦ low risk of bias (participants/personnel blinded to
allocated intervention; and unlikely that blinding broken);
◦ unclear risk of bias (insufficient information to permit
judgement of low/high risk of bias);
◦ high risk of bias (participants/personnel not blinded to
allocated intervention, two interventions clearly identifiable to
personnel as experimental and control OR participants/
personnel blinded to allocated intervention but it is likely that
blinding may have been broken).
• Blinding of outcome assessor (detection bias). We
assessed the methods used to blind outcome assessors as:
◦ low risk of bias (outcome assessor (including
’participants’ with respect to self-report outcomes) blinded to
participants’ allocated interventions and unlikely that blinding
broken);
◦ unclear risk of bias (insufficient information to permit
judgement of low/high risk of bias);
◦ high risk of bias (outcome assessor (including
’participants’ with respect to self-report outcomes) unblinded to
participants’ allocated interventions OR outcome assessor
blinded to allocated intervention but likely that blinding may
have been broken).
• Incomplete outcome data (attrition bias). We assessed
attrition bias by considering if participant dropout rate was
appropriately described and acceptable:
◦ low risk of bias (less than 20% dropout and appeared
to be missing at random. Numbers given per group and reasons
for dropout described);
◦ unclear risk of bias (if less than 20% but reasons not
described and numbers per group not given. Unclear that data
were missing at random);
◦ high risk of bias (if over 20% even if imputed
appropriately).
• Incomplete outcome data (participant exclusion). We
assessed whether participants were analysed in the group to
which they were allocated as:
◦ low risk of bias (if analysed data in group to which
originally assigned with appropriately imputed data or as an
available-case analysis);
◦ unclear risk of bias (insufficient information provided
to determine if analysis was per protocol or intention to treat);
◦ high risk of bias (if per-protocol analysis used. Where
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available data were not analysed or participant data were
included in group they were not originally assigned to).
• Selective reporting (reporting bias). We assessed whether
studies were free of the suggestion of reporting bias as:
◦ low risk of bias (study protocol available and all
prespecified outcomes of interest adequately reported; study
protocol not available but all expected outcomes of interest
adequately reported; all primary outcomes numerically reported
with point estimates and measures of variance for all time points);
◦ unclear risk of bias (inadequate information to allow
judgement of a study to be classified as ’low risk’ or ’high risk’);
◦ high risk of bias (incomplete reporting of prespecified
outcomes; one or more primary outcomes was reported using
measurements, analysis methods or subsets of data that were not
prespecified; one or more reported primary outcomes were not
prespecified; one or more outcomes of interest reported
incompletely and cannot be entered into a meta-analysis; results
for a key outcome expected to have been reported excluded).
• Size of study (checking for possible biases confounded by
small sample size). We assessed studies as:
◦ low risk of bias (200 participants or more per
treatment arm);
◦ unclear risk of bias (50 to 199 participants per
treatment arm);
◦ high risk of bias (fewer than 50 participants per
treatment arm).
• Other sources of bias. We also assessed other risk factors
such as whether trials were stopped early, differences between
groups at baseline, differences between groups in timing of
outcome assessment, insufficient control of cointerventions and
author source of funding declarations.

within-person change from baseline that participants might consider clinically important, whereas the studies in this review typically presented effect sizes as the mean between-group change.
There is little consensus or evidence regarding what the threshold should be for a clinically important difference in pain intensity based on the between-group difference postintervention. For
some pharmacological interventions, the distribution of participant outcomes is bimodally distributed (Moore 2013). That is,
some participants experience a substantial reduction in symptoms
(Moore 2014), some experience minimal to no improvement and
very few experience intermediate (moderate) improvements. In
this instance, and if the distribution of participant outcomes reflects the distribution of treatment effects, then the mean effect
may be the effect that the fewest participants actually demonstrate (Moore 2013). Therefore, it is possible that a small mean
between-group effect size might reflect that a proportion of participants responded very well to the intervention tested. It is unknown whether outcomes are commonly bimodally distributed
in trials of TENS and the advantage of focusing on the betweengroup difference is that it is the only direct estimate of the mean
specific effect of the intervention. Equally, it remains possible that
a very small mean between-group effect might accurately represent generally very small effects of an intervention for most or all
individuals.
The OMERACT 12 group have reported recommendations for
minimally important difference for pain outcomes (Busse 2015).
They recommend 10 mm on a 0 mm to 100 mm VAS as the threshold for minimal importance for mean between-group change
though they stress this should be interpreted with caution as it
remains possible that estimates that fall closely below this point
may still reflect a treatment that benefits an appreciable number of
people. We use this threshold but interpret it appropriately given
the quality of the included studies.

Measures of treatment effect
We analysed primary outcomes and presented this on a continuous scale as mean difference (MD) with 95% confidence intervals
(CI). Where data were available, we planned to present outcomes
in a dichotomised format. For dichotomised data (responder analyses), we planned to consider analyses based upon a 30% or greater
reduction in pain to represent a moderately important benefit, and
a 50% or greater reduction in pain intensity to represent a substantially important benefit as suggested by the IMMPACT guidelines
(Dworkin 2008). Where possible, we planned to present risk ratio
(RR) and risk difference (RD) with 95% CIs for dichotomised
outcome measures. We planned to calculate the number needed
to treat for an additional beneficial outcome (NNTB) as an absolute measure of treatment effect. However, these data were not
available in the included studies. For HRQoL data, we preplanned
a minimally important clinical difference to be greater than 10%
of the scale employed (Furlan 2009), however we were unable to
report on HRQoL.
The IMMPACT thresholds are based on estimates of the degree of

Unit of analysis issues
In cross-over studies, we planned to use first period data only wherever possible (Higgins 2011). Where this was not reported, we undertook analysis as if the treatment periods were parallel and highlighted the potential bias this may have introduced. All included
studies randomised at the level of the individual participant.

Dealing with missing data
Where insufficient data were presented to enter into an otherwise
viable meta-analysis, we contacted the study authors. Two included
studies did not present data in a format suitable for data extraction.
One study author replied with further data (Buchmuller 2012).
We were unable to contact the authors of one further study (
Prabhakar 2011).
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Assessment of heterogeneity
We planned to combine studies that examined similar conditions.
However, given the limited number of studies, we pooled data from
studies in different neuropathic pain conditions but have considered whether diagnostic group appears to be a source of important
heterogeneity. We evaluated the included studies for clinical homogeneity regarding study population, treatment procedure, control intervention, timing of follow-up and outcome measurement.
We did not combine studies that compared TENS to usual care
with studies that compared TENS to sham/placebo in the same
analysis. We formally explored heterogeneity using the Chi² test
to investigate the statistical significance of any heterogeneity, and
the l² statistic to estimate the amount of heterogeneity. Where
significant heterogeneity (P < 0.1) was present, we planned to explore subgroup analyses. Preplanned comparisons are described in
Subgroup analysis and investigation of heterogeneity.

Assessment of reporting biases
We planned to consider the possible influence of publication/small
study biases on review findings. The influence of small study biases were, in part, addressed by the risk of bias criterion ’study
size.’ We planned to use funnel plots to visually explore the likelihood of reporting biases when there were at least 10 studies in a
meta-analysis and included studies differ in size. For continuous
outcomes, we planned to use Egger’s test to detect possible small
study bias and, for dichotomised outcomes, we planned to test
for the possible influence of publication bias on each outcome by
estimating the number of participants in studies with zero effect
required to change the NNTB to an unacceptably high level (defined as a NNTB of 10), as outlined by Moore 2008. Given the
small number of studies in the meta-analysis and that the remaining studies investigated different TENS comparisons, we did not
undertake the above processes.

Data synthesis
We extracted data and classified them according to outcome and
duration of follow-up (during-use effects; short term: zero to less
than two weeks postintervention; mid-term: two to seven weeks
postintervention; and long term: eight or more weeks postintervention). Where adequate data existed, we used a random-effects
model to meta-analyse outcome data from suitably homogeneous
studies using Review Manager 5 (RevMan 2014). For the pooled
analysis, pain intensity data was extracted as 0-10 VAS rating scale
except one study which used a 0-100 VAS scale (Barbarisi 2010).
For this study, we converted the results to a 0-10 scale by dividing
the measure by 10. The pooled effect sizes for changes in pain
intensity were presented as MDs. We planned to pool data for
adverse events across conditions though adequate data were not
available to do so. We considered meta-analysis appropriate for
only one comparison (TENS versus sham TENS). This decision

reflects the clinical diversity across the included studies, particularly in relation to the control condition. We described the remaining studies as a narrative synthesis. We used the GRADE system
to summarise the quality of the body of evidence for key comparisons (Guyatt 2008).
• Limitations of studies: downgraded once if greater than
25% of participants were from studies at high risk of bias across
any key ’Risk of bias’ criteria.
• Inconsistency: downgraded once if heterogeneity was
statistically significant and I2 ≥ 40% or when reported treatment
effects were in opposition directions.
• Indirectness: downgraded once if greater than 50% of the
participants were outside the target group.
• Imprecision: downgraded once if fewer than 400
participants for continuous data and fewer than 300 events for
dichotomous data (Guyatt 2011).
• Publication bias: downgrade once where there was direct
evidence of publication bias.
We considered single studies both inconsistent and imprecise (unless sample size was greater than 400 participants for continuous data and greater than 300 events for dichotomous data). Two
review authors (WG and BW) made these judgements independently and we resolved disagreements by discussion. A third review
author (NEO) was available if agreement could not be reached.
This option was not required.
The GRADE system uses the following criteria for assigning grade
of evidence:
• high: we are very confident that the true effect lies close to
that of the estimate of the effect;
• moderate: we are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of
effect, but there is a possibility that it is substantially different;
• low: our confidence in the effect estimate is limited; the
true effect may be substantially different from the estimate of the
effect;
• very low: we have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect.
We included a ’Summary of findings’ table to present the main
findings for the comparison ’TENS versus sham TENS’ in a transparent and simple tabular format. In particular, we included key
information concerning the quality of evidence, the magnitude
of effect of the intervention examined and the sum of available
data on the outcome(s). Due to clinical heterogeneity and lack
of studies, we were unable to compare TENS versus usual care,
TENS versus no treatment or TENS in addition to usual care
versus usual care alone, therefore we did not present ’Summary of
findings’ tables for these comparisons.

Subgroup analysis and investigation of heterogeneity
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We planned subgroup analysis in the following domains:
• type of neuropathic pain: central neuropathic pain (pain
due to identifiable pathology of the central nervous system (e.g.
stroke, spinal cord injury) or peripheral neuropathic pain (pain
resulting from pathology of the nerve root or peripheral nerves);
• type of neuropathic condition (as feasible from included
studies);
• stimulation parameters: intensity (subgroup studies in
which intensity was titrated to a strong sensation versus studies
in which intensity was not titrated);
• stimulation parameters: frequency (low frequency TENS 10
Hz or less versus high frequency TENS 100 Hz or greater).
We did not undertake these analyses due to insufficient number of
included studies and for the pooled analysis clinical homogeneity.

Sensitivity analysis
We undertook a sensitivity analysis on risk of bias (investigating
the effect of including/excluding studies at high risk of bias from
the analysis) and the choice of meta-analysis model (investigating
the impact of applying a fixed-effect instead of a random-effects
model) for the comparison TENS versus sham TENS. We described all other studies narratively.

and WG) assessed for inclusion/exclusion (Pourmomeny 2009).
See Figure 1 for a summary of the screening process.
Included studies
A detailed description of all studies included in this review is provided in the Characteristics of included studies table, and detailed
descriptions of participants and TENS treatment parameters in
individual studies (where reported) can be found in Table 1. We
included 15 studies and extracted data from 14 of these. One
study did not provide useable data (Rutgers 1988). We contacted
two study authors with respect to clarifications around published
data. On request, Barbarisi 2010 provided detail on post-treatment VAS pain intensity score variance; Buchmuller 2012 provided clarification on the process of subgrouping of participants
into a neuropathic pain group and data on VAS pain intensity for
this group. Nabi 2015 provided methodological information with
respect to outcome assessment timeframe postintervention. We
contacted two study authors regarding clarification of published
data but received no response (Prabhakar 2011; Serry 2015). Lack
of up to date contact information meant one study author could
not be contacted (Rutgers 1988).
A detailed narrative description of all included studies can be found
in Appendix 2.
Design

RESULTS
Description of studies
For a detailed description of all studies see Characteristics of
included studies and Characteristics of excluded studies table.

Results of the search
The literature search was conducted in September 2016 and found
4081 records. We removed duplicates and were left with 2330
study records. Two review authors (BW and WG) then independently reviewed titles and abstracts of all study records against inclusion and exclusion criteria. These independent selections were
compared and consensus reached over study inclusion/assessment
of full text papers. We selected 46 records for further investigation in full-text format and from this agreed on 15 papers to include in the review (Barbarisi 2010; Bi 2015; Buchmuller 2012;
Casale 2013; Celik 2013; Gerson 1977; Ghoname 1999; Koca
2014; Nabi 2015; zkul 2015; Prabhakar 2011; Rutgers 1988;
Serry 2015; Tilak 2016; Vitalii 2014). One review author (BW)
translated and conducted inclusion/exclusion criteria for two papers with the help of a native German speaker (Heidenreich 1988;
Lehmkuhl 1978); a volunteer identified through Cochrane Task
Exchange translated another study, which two review authors (BW

All studies included in the review were RCTs. Of these, we considered five were appropriate to pool data for the comparison of
TENS versus sham (Barbarisi 2010; Bi 2015; Buchmuller 2012;
Celik 2013; Vitalii 2014). Each of these five were two arm parallel designs with TENS versus sham TENS. The remaining 10
studies were RCTs with two parallel intervention arms (Casale
2013; Gerson 1977; Nabi 2015; Rutgers 1988; Tilak 2016), three
parallel intervention arms (Koca 2014; Prabhakar 2011), or were
randomised cross-over designs with either two ( zkul 2015), or
three sequenced interventions (Ghoname 1999).
Participants

The 15 studies included 728 participants at intake. Seven of the included studies did not have a formal mechanism employed to classify/diagnose participants (Barbarisi 2010; Bi 2015; Gerson 1977;
Prabhakar 2011; Rutgers 1988; Serry 2015; Tilak 2016). Two
studies employed confirmatory nerve conduction studies (Casale
2013; Koca 2014), two used the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) scale (Celik 2013; Vitalii
2014), and one study used the Douleur Neuropathique 4 (DN4)
questionnaire ( zkul 2015). Three studies classified participants
by clinical assessment (Buchmuller 2012; Ghoname 1999; Nabi
2015). Within participants, neuropathic pain was associated with
spinal cord injury in four studies (Bi 2015; Celik 2013; zkul
2015; Vitalii 2014), PHN in three studies (Barbarisi 2010; Gerson
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1977; Rutgers 1988), sciatica/chronic low back pain in two studies (Buchmuller 2012; Ghoname 1999), carpal tunnel syndrome
in two studies (Casale 2013; Koca 2014), PDN in two studies
(Nabi 2015; Serry 2015), phantom limb pain in one study (Tilak
2016), and cervical radiculopathy in one study (Prabhakar 2011).
Baseline pain intensity was not part of the inclusion criteria for
this review, however these data are reported in Table 1.
Interventions

There was considerable diversity in the comparisons and parameters of TENS application in terms of frequency of applied TENS,
intensity of TENS, electrode position, and frequency and duration of application (see Table 1 for a summary of intervention
characteristics). Five studies compared TENS with sham TENS
and were considered suitable for pooling. These five studies used
’no current’ as the sham condition. Electrode placement and the
device itself were identical to active TENS. Two studies attempted
to maintain participant blinding by informing participants that
a sensation may or may not be felt (Barbarisi 2010; Buchmuller
2012), while two studies failed to include details on managing
participant intervention expectations (Bi 2015; Vitalii 2014). One
study applied TENS/sham TENS below the site of injury in participants with spinal cord injury meaning no participants reported
sensation during TENS application and used this as evidence for
adequate sham (Celik 2013). Two studies used sham TENS devices
which delivered no current but appeared to be switched on and
’live’ (Buchmuller 2012; Vitalii 2014). Two studies did not include
detail on this and it could not be assumed the sham TENS device
appeared to the participant to be switched on. Lastly, in four of the
five studies in the pooled analysis the clinical personnel were not
blinded to treatment (Barbarisi 2010; Bi 2015; Celik 2013; Vitalii
2014). No studies compared TENS with no treatment, or TENS
in addition to usual care with usual care alone. All remaining studies compared TENS against usual care and employed a range of
active treatments in the comparison group. The different types of
comparison may be categorised as TENS versus other electrotherapy modalities (Casale 2013; Ghoname 1999; Koca 2014), TENS
versus sensory-motor rehabilitation strategies ( zkul 2015; Tilak
2016), TENS versus manual therapy (Prabhakar 2011), TENS
versus acupuncture (Rutgers 1988), TENS versus exercise (Serry
2015), and TENS versus pharmacotherapy (Gerson 1977). See
Table 1 for a summary of study participants, comparisons and
conditions studied.
Outcomes

All five studies used in the pooled analysis assessed pain intensity
immediately postintervention and are all therefore classified as assessing short-term outcome. Four of the five studies reported VAS
using a 0-10 scale while one study used a 0-100 scale (Barbarisi
2010). In the pooled analysis, outcome assessment occurred immediately postintervention period which varied in length from 10

days (Celik 2013; Vitalii 2014) to four weeks (Barbarisi 2010) to
three months (Bi 2015; Buchmuller 2012).
The majority of studies included in the narrative synthesis assessed
pain intensity on a 0-10 VAS scale immediately postintervention,
(Casale 2013; Ghoname 1999; zkul 2015; Prabhakar 2011; Serry
2015; Tilak 2016). Within this group, the length of intervention
varied in duration from four days (Tilak 2016) to two weeks ( zkul
2015), three weeks (Casale 2013; Ghoname 1999; Prabhakar
2011), and eight weeks (Serry 2015).
One study assessed pain intensity at three weeks’ postintervention therefore reporting mid-term effects (Koca 2014), and one
study reported pain intensity at one week’, one month’ and three
months’ postintervention covering short, mid and long term outcome effects (Nabi 2015).
Only one study assessed during use effects, with pain intensity
(0-100 VAS scale) reported at week eight of an overall 10 week
intervention protocol (Gerson 1977). Lastly, one study reported
assessment of pain intensity using a 10 point stepwise scale at six
weeks, nine weeks and six months; however, no useable data were
presented (Rutgers 1988).
Two studies collected data on HRQoL (Buchmuller 2012;
Ghoname 1999). However, we were unable to use these data.
No studies reported on PGIC. Three studies monitored/reported
on medication use; however, we were unable to analyse the data
further. Lastly, three studies reported on minor skin irritation as
adverse events (Buchmuller 2012; Koca 2014; Nabi 2015). Further detail regarding these outcomes is supplied in the Effects of
interventions section.

Excluded studies
A list of the 31 excluded studies and reasons for exclusion is provided in the Characteristics of excluded studies table. In summary,
reasons for exclusion were as follows: not definitive neuropathic
pain participants (nine studies); not an RCT or follow-up less than
24 hours postrandomisation (nine studies); composite outcome
measures involving pain and other sensory measures/symptoms
(10 studies); standard TENS unit not used (two studies) and treatment delivered at subperceptual levels (one study).

Studies awaiting classification
One paper is awaiting translation and is currently recorded as
awaiting classification (Wang 2009). A search of clinical trials registries and abstracts yielded three registered trials and one thesis
of interest. We contacted study authors for all three trials. Two
authors replied and following this these trials were excluded. We
have contacted authors of the remaining trial and the thesis without reply (ICTRPNCT02496351; Samier 2006). These results are
recorded as awaiting classification. See Characteristics of studies
awaiting classification table.
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Ongoing studies
The search identified no ongoing studies.

Risk of bias in included studies
We present a ’Risk of Bias’ summary for all included studies in
Figure 2, followed by an individual graphical representation for
every study across each ’Risk of Bias’ domain (Figure 3). In summary, we judged 11 studies as being at high risk of bias overall
(Barbarisi 2010; Bi 2015; Celik 2013; Gerson 1977; Ghoname
1999; Koca 2014; Nabi 2015; Prabhakar 2011; Rutgers 1988;
Serry 2015; Vitalii 2014). We judged the remaining four studies at
unclear risk of bias (Buchmuller 2012; Casale 2013; zkul 2015;
Tilak 2016).
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation

Random sequence generation

We judged six out of the 15 included studies to have adequately
described random sequence generation and we classified them as
low risk for selection bias (Barbarisi 2010; Bi 2015; Buchmuller
2012; Casale 2013; zkul 2015; Tilak 2016). Seven studies did
not provide sufficient detail to allow a judgement to be made
with regard to sequence generation and we judged them to be at
unclear risk of bias (Gerson 1977; Ghoname 1999; Nabi 2015;
Prabhakar 2011; Rutgers 1988; Serry 2015; Vitalii 2014). Two
studies used alternate/sequential allocation to treatment groups
and we therefore judged them to be at high risk for selection bias
(Celik 2013; Koca 2014).

Allocation concealment

The majority of studies did not provide sufficient detail to allow
judgement with respect to allocation concealment and we assigned
them unclear risk of bias (Barbarisi 2010; Bi 2015; Casale 2013;
Gerson 1977; Nabi 2015; Prabhakar 2011; Rutgers 1988; Serry
2015; Vitalii 2014). We deemed two studies to be at high risk
for allocation concealment (Celik 2013; Koca 2014). Two studies
were cross-over designs and we therefore judged them to be at
low risk for selection bias (Ghoname 1999; zkul 2015, while we
judged two parallel controlled trials to have adequately described
allocation concealment and were designated low risk of bias in
allocation concealment (Buchmuller 2012; Tilak 2016).

Blinding

Blinding of participants/personnel (care providers)

For each study, we assessed and judged blinding of participants
and blinding of personnel separately. When completing ’Risk of
bias’ tables (where these ratings are combined into one domain) we
adhered to the following guideline: where either the participants or
personnel were considered to be inadequately blinded we judged
the section overall to be at high risk of bias. This was the case for
nine out of the 14 studies (Barbarisi 2010; Bi 2015; Celik 2013;
Gerson 1977; Ghoname 1999; Koca 2014; Nabi 2015; Rutgers
1988; Vitalii 2014). One study described adequate blinding of
both participants and personnel and was deemed at low risk of bias
(Buchmuller 2012). Five studies made comparisons against other
comparable active treatments and we assigned unclear risk of bias
to blinding of participants and personnel in these studies (Casale
2013; zkul 2015; Prabhakar 2011; Serry 2015; Tilak 2016).

Blinding of outcome assessors

We judged two of the five studies in the pooled analysis investigating changes in pain intensity with TENS versus sham TENS
at low risk of bias (Buchmuller 2012; Celik 2013). We rated the
remaining three studies in the pooled analysis at unclear risk of
bias in this domain (Barbarisi 2010; Bi 2015; Vitalii 2014). We
considered studies applying two active comparable treatments at
unclear risk for this domain (Casale 2013; zkul 2015; Prabhakar
2011; Serry 2015; Tilak 2016), while we judged studies applying invasive or non-comparable treatments compared to TENS at
high risk of bias (Gerson 1977; Ghoname 1999; Koca 2014; Nabi
2015; Rutgers 1988).

Incomplete outcome data
With regard incomplete outcome data, we separately considered
risk of bias assessment for ’attrition’ and ’participation exclusion’
domains. However, in a number of studies ’participant exclusion’
was not explicitly described. In response to this, we used the following guideline when judging ’attrition’ and ’participant exclusion’ bias: if ’participant exclusion’ was not explicitly described but
the ‘attrition’ was minor or acceptable and reasonably described,
we used this as justification for low risk across both domains. If ’attrition’ or ’participant exclusion’ was not adequately described or
explained, this was used as justification for the unclear risk ’participant exclusion from analysis’ decision for the studies Nabi 2015,
Prabhakar 2011, Serry 2015, and Vitalii 2014. Furthermore, we
judged one cross-over study at unclear risk of bias as no mention
was made with regard to any missing data over the many hundreds
of data collection points (Ghoname 1999).
Six studies adequately described both sections in this domain and
we judged them at low risk of bias (Barbarisi 2010; Bi 2015; Casale
2013; Celik 2013; zkul 2015; Tilak 2016). One study specifically
excluded participants lost to follow-up and we therefore judged
high risk on ’participant exclusion’ bias (Koca 2014). Two studies reported very significant attrition and employed ’per protocol’
analysis and we judged these at high risk of bias across both domains (Gerson 1977; Rutgers 1988). We obtained data for a neuropathic subgroup of participants in one study, of which there was
around 38% loss of outcome data at post-treatment assessment
and therefore we judged this study at high risk of attrition bias
(Buchmuller 2012).

Selective reporting
We considered eight studies to have adequately reported across all
outcome measures and were judged at low risk of bias (Bi 2015;
Casale 2013; Celik 2013; Koca 2014; Nabi 2015; zkul 2015;
Tilak 2016; Vitalii 2014. Inconsistencies in presented data led us
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to judge two studies at unclear risk (Barbarisi 2010; Buchmuller
2012). Five studies did not adequately describe or present all stated
outcome measures and were assigned high risk of bias in this area
(Gerson 1977; Ghoname 1999; Prabhakar 2011; Rutgers 1988;
Serry 2015).

Other potential sources of bias
We focused on two main factors in this risk of bias section and
judged whether baseline characteristics and outcome measure time
frames were adequate and comparable. We judged six studies at
low risk of bias in this domain (Bi 2015; Buchmuller 2012; Casale
2013; Celik 2013; Tilak 2016; Vitalii 2014). Two studies did not
provide any data about baseline characteristics between groups and
we assigned at high risk of bias (Gerson 1977; Prabhakar 2011).
Seven studies were at unclear risk due to insufficient detail around
baseline comparisons or outcome measure timing (Barbarisi 2010;
Ghoname 1999; Koca 2014; Nabi 2015; zkul 2015; Rutgers
1988; Serry 2015).

Size of study

We deemed 13 studies to be at high risk of bias with fewer
than 50 participants per treatment arm (Barbarisi 2010; Bi 2015;
Casale 2013; Celik 2013; Gerson 1977; Koca 2014; Nabi 2015;
zkul 2015; Prabhakar 2011; Rutgers 1988; Serry 2015; Tilak
2016; Vitalii 2014. We assigned two studies unclear risk of bias
as their sample size was between 50 and 200 per treatment arm
(Buchmuller 2012) or as part of a cross-over trial (Ghoname 1999).

Effects of interventions

See: Summary of findings for the main comparison TENS
versus sham TENS
TENS versus sham TENS

Primary outcomes

Change in pain intensity
We included five individual studies that reported change in pain
intensity (n = 207) (Barbarisi 2010; Bi 2015; Buchmuller 2012;
Celik 2013; Vitalii 2014). Sample sizes ranged from n = 21 (Vitalii
2014), up to n = 122 (Buchmuller 2012). One two-arm parallel design investigated TENS versus sham TENS in participants
with PHN (Barbarisi 2010). Three studies ran two-arm parallel
group designs in participants with spinal cord injury (Bi 2015;
Celik 2013; Vitalii 2014). One study investigated TENS versus
sham TENS in participants with chronic radicular low back pain
(Buchmuller 2012).
When pooling the data, we entered the pain intensity scores from
Barbarisi 2010 as two distinct comparisons: pregabalin 300 mg
plus TENS versus pregabalin 300 mg plus sham TENS and pregabalin 600 mg plus TENS versus pregabalin 600 mg plus sham
TENS. We considered this a valid approach because it did not
cause any unit of analysis issues as it was a parallel study design
and participants were not ’double counted.’
For pain intensity (expressed on a 0-10 scale) pooling of the studies
using a random-effects model yielded an MD effect size favouring
TENS of -1.58 (95% CI -2.08 to -1.09, P < 0.00001, n = 207,
6 comparisons from 5 studies; very low quality evidence). There
was no significant heterogeneity (see Figure 4).

Figure 4. Forest plot of comparison: 1 TENS versus sham TENS, outcome: 1.1 Changes in pain intensity.
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Sensitivity analysis yielded the following effect size when using
a fixed-effect model (MD -1.57, 95% CI -1.97 to -1.16, P <
0.00001, n = 207, 6 comparisons from 5 studies). Given that we
rated the key domains of selection and blinding bias domains as
high risk for Celik 2013, we investigated the effect of study quality
on the pooled estimate by removing this study from the pooled
analysis (see Figure 5). This yielded an effect size of -1.44 (95%
CI -1.87 to - 1.02, P < 0.001, n = 174, 5 comparisons from 4
studies).
Figure 5. Forest plot of comparison: 1 TENS versus sham TENS, outcome: 1.2 Pain intensity sensitivity
analysis (Celik 2013 removed).

With regard to a relative comparison of effect size, three of the five
studies in the pooled comparison used concomitant drug treatment and we considered that it would be inappropriate to use
these as comparators of effect size. Therefore, using the randomeffects result, an MD of -1.58 when expressed relative to the mean
baseline values of the study with the largest control group sample
size Buchmuller 2012 (n = 58) equated to a 26% reduction in pain
intensity post-treatment (95% CI 18% to 34%). Overall, the MD
exceeded the 1 unit suggested to be the minimally important difference in between-group change scores for pain intensity (Busse
2015).
The very low quality evidence (downgraded due to significant
limitations of studies and imprecision) means it is impossible to
confidently state whether TENS has a pain relieving effect compared to sham TENS in people with neuropathic pain at shortterm postintervention follow-up. The true effect is very likely to
be significantly different from the estimate reported.
Changes in health related quality of life
Four of the five studies in the pooled analysis did not investigate
HRQoL (Barbarisi 2010; Bi 2015; Celik 2013; Vitalii 2014). The
remaining study, whilst assessing HRQoL via the SF-36 questionnaire, did not present baseline data, did not provide neuropathic
subgroup data and reported the SF-36 broken into separate phys-

ical and mental domains (Buchmuller 2012). Therefore, we were
unable to report on HRQoL in this comparison.

Secondary outcomes

Changes in participant global impression of change
No studies reported PGIC.

Change in analgesic medication use
One study assessed concurrent gabapentin use in both TENS and
sham TENS groups and reported increases in both (Vitalii 2014).
The TENS group increased by a mean of approximately 136 mg
of gabapentin while the sham TENS group increased by a mean of
560 mg of gabapentin. This difference in increase was reported as
statistically significant but no variance data were given. Pregabalin
was used concurrently in another study but there were no comparisons made or planned across pharmacological data (Barbarisi
2010). Drug use was monitored but not explicitly reported or analysed postintervention in a third study (Buchmuller 2012). Two
studies did not include medication use as an outcome (Bi 2015;
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Celik 2013). Overall, we could make no conclusions on the effect
of TENS versus sham TENS with respect to medication use.

Secondary outcomes

Changes in participant global impression of change
Incidence/nature of adverse events
Two studies explicitly reported no adverse events associated with
TENS treatment (Celik 2013; Vitalii 2014). One study reported
minor skin irritation in 11 participants in the active group versus
three participants in the sham group. These data related to the
whole study which included people without defined neuropathic
related pain (Buchmuller 2012). Two studies did not report adverse events (Barbarisi 2010; Bi 2015). We could make no overall
conclusion from this with regard to adverse events associated with
TENS versus sham TENS.

The study did not report PGIC.

Change in analgesic medication use
The study did not report change in medication use.

Incidence/nature of adverse events
The study did not report adverse events.

TENS versus carbamazepine plus clomipramine
Planned comparisons
Due to a lack of data we were unable to report on comparisons
for TENS versus no treatment or TENS in addition to usual care
versus usual care alone. We identified 10 studies that compared
TENS to usual care; however, there was great diversity in the treatment provided in the usual care arm of these studies precluding
any quantitative data synthesis. A narrative summary of each of
these studies is presented below.

We found one study that compared TENS versus carbamazepine
plus clomipramine (Gerson 1977).

Primary outcomes

Change in pain intensity

Casale 2013 investigated TENS versus laser in participants with
carpal tunnel syndrome. The study reported a statistically significant time-by-group ANOVA interaction indicating statistically
significant differences in post-treatment change in pain intensity
scores (VAS 0-10) between the laser and TENS groups. Our calculations indicated an MD of -1.2 in favour of laser compared to
TENS (95% CI -2.3 to -0.1, P = 0.041).
We found very low quality evidence (downgraded for limitations
of study, inconsistency and imprecision) that laser may be more
effective than TENS for treatment of pain at short-term postintervention follow-up in participants with carpal tunnel syndrome.

Gerson 1977 investigated TENS versus pharmacological intervention (carbamazepine plus clomipramine) in participants with
PHN. Analysis of the results was performed on a per-protocol
basis and there was a 60% attrition rate across the whole sample. Final analysis was performed on 12 participants for the drug
group (including three participants who were initially randomised
to TENS) and four participants for the TENS group (including
one participant who was initially randomised to drug treatment).
VAS values (0-100) at week eight were reported as means and
standard errors of the mean (drug group 21 ± 4.3 mm, TENS
group 43 ± 15.6 mm). The study reported this as a statistically
significant difference although there was no information on the
tests employed.
There was very low quality evidence (downgraded for limitations
of study, inconsistency and imprecision) that carbamazepine plus
clomipramine drug treatment may be more effective than TENS
for treatment of pain in participants with PHN. It should be noted
that the drug intervention was completed by week eight and all
remaining participants were assessed at this stage. Thus, results
reported for the drug arm of this study were short-term postintervention effects while the TENS result related to ’during use’ effects
as the TENS final treatment was not delivered until week 10 of
the protocol.

Changes in health related quality of life

Changes in health related quality of life

The study did not report HRQoL.

The study did not report HRQoL.

TENS versus therapeutic laser
We found one study that compared TENS with laser (Casale
2013).

Primary outcomes

Change in pain intensity
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Secondary outcomes

Changes in participant global impression of change
The study did not report PGIC.

Secondary outcomes

Changes in participant global impression of change
The study did not report PGIC.

Change in analgesic medication use
The study reported drug dosage data for participants who competed the protocol as being carbamazepine 150 mg /day to 1000
mg/day and clomipramine 10 mg/day to 75 mg/day. No further
analysis or change in analgesic use reported.

Change in analgesic medication use

The study did not report adverse events.

Oral non-opioid analgesic tablet consumption/day reduced by
(mean ± SD) 50 ± 19% in the PENS group and 29 ± 17% in the
TENS group post-treatment compared to pretreatment for each
phase: for PENS this equated to a reduction of approximately 1
tablet/day on average (approximately 2.5 tablets/day to 1.5 tablets/
day). The study did not report any statistical analysis for this result.

TENS versus percutaneous electrical nerve
stimulation

Incidence/nature of adverse events

Incidence/nature of adverse events

We found one study comparing TENS versus PENS (Ghoname
1999).

The study did not report adverse events.

TENS versus interferential therapyversus splints
Primary outcomes

We found one study comparing TENS versus IFT (Koca 2014).

Change in pain intensity
Ghoname 1999 investigated PENS versus TENS in participants
with sciatica. The study reported a significant reduction in pain
intensity (VAS 0-10) post-treatment for both PENS and TENS.
The study reported pain intensity 24 hours post-treatment as significantly lower for PENS compared to TENS (mean ± SD: 4.1
± 1.4 with PENS versus 5.4 ± 1.9 with TENS). This may be expressed as an MD of -1.3 (95% CI -1.9 to -0.7, P < 0.0001) in
favour of PENS compared to TENS.
There was very low quality evidence (downgraded for limitations
of study, inconsistency and imprecision) that PENS may be more
effective than TENS for treatment of pain at short-term post-intervention follow-up in participants with radicular pain secondary
to sciatica.
Changes in health related quality of life
Data for quality of life (SF-36) were collected at baseline across all
participants and scores reported as physical component summary
(PCS) and mental component summary (MCS). The SF-36 was
then completed again, 24 hours after completion of all nine treatments of each modality. A repeat baseline SF-36 was not reported
prior to each subsequent treatment phase with all post-treatment
PCS/MCS scores being compared to the single original baseline
assessment. We considered this to be sufficiently problematic such
that we did not consider these data further.

Primary outcomes

Change in pain intensity
Koca 2014 investigated TENS versus IFT versus night splints in
participants with carpal tunnel syndrome. There was a statistically
significant difference (from baseline) in pain intensity (VAS 0-10)
for all three interventions post-treatment. The study reported that
IFT post-treatment scores were significantly lower than scores for
TENS or splint interventions (mean ± SD: 6.4 ± 1.2 with splint,
6.7 ± 1.4 with TENS, 4.80 ± 1.2 with IFT). This represented an
MD of -0.3 (95% CI -1.1 to 0.5, P = 0.95) between TENS and
splint treatment. In terms of the two active treatments (TENS
and IFT), there was an MD of -1.88 (95% CI -2.68 to -1.07, P
< 0.0001) in favour of IFT. There were two minor adverse events
(skin irritation) in the TENS group.
There was very low quality evidence (downgraded for limitations
of study, inconsistency and imprecision) that IFT may be more effective than TENS for treatment of pain at medium-term postintervention follow-up in participants with carpal tunnel syndrome.

Changes in health related quality of life
The study did not report HRQoL.
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Secondary outcomes

Change in analgesic medication use
The study did not report drug use.

Changes in participant global impression of change
The study did not report PGIC.

Incidence/nature of adverse events
Skin irritation was “reported in a few” TENS participants.

Change in analgesic medication use
The study did not report drug use.

TENS versus visual illusion
We found one study comparing TENS with visual illusion (VI)
( zkul 2015).

Incidence/nature of adverse events
There were two minor adverse events (skin irritation) in the TENS
group.

TENS versus pulsed radiofrequency sympathectomy
We found one study comparing TENS versus pulsed radiofrequency (PRF) sympathectomy (Nabi 2015).

Primary outcomes

Change in pain intensity
Nabi 2015 investigated PRF sympathectomy versus TENS in participants with diabetic peripheral neuropathy. At the postprocedure reassessment points, the mean pain intensity (NRS 0-10) results were as follows: one week: 2.76 with PRF sympathectomy,
3.96 with TENS; one month: 4.3 with PRF sympathectomy, 5.23
with TENS; three months: 5.13 with PRF sympathectomy, 5.90
with TENS. There was no indication of variance for the NRS
scores. There was no testing of the difference between groups reported.
We judged this study as presenting very low quality evidence
(downgraded for limitations of study, inconsistency and imprecision) given the lack of data presented and the analysis being
’within-group’ only. Based on this, we were unable to draw any
conclusions on the relative efficacy of each investigated treatment
on pain in people with peripheral diabetic neuropathy.

Primary outcomes

Change in pain intensity
zkul 2015 investigated TENS versus VI in participants with pain
secondary to spinal cord injury. The study reported a significant
difference of ’present’ pain intensity (VAS 0-10) post day-10 treatment between interventions (mean ± SD): 3.66 ± 1.52 with TENS,
4.66 ± 1.37 with VI). However, from our calculations, this represents a non-significant MD of 1.0 (95% CI -0.16 to 2.15, P = 0.1).
Within-treatment analyses were reported as statistically significant
in the domains of maximal and minimal pain for TENS only.
However, between-group testing was not significantly different for
the two groups for mean, maximal or minimal pain intensity posttreatment.
There was very low quality evidence (downgraded for limitations
of study, inconsistency and imprecision) that VI was no more effective than TENS for treatment of pain at short-term postintervention follow-up in participants with neuropathic pain following
spinal cord injury.

Changes in health related quality of life
The study did not report HRQoL.

Secondary outcomes

Changes in participant global impression of change
Changes in health related quality of life

The study did not report PGIC.

The study did not report HRQoL.
Change in analgesic medication use
Secondary outcomes

The study did not report drug use.

Changes in participant global impression of change

Incidence/nature of adverse events

The study did not report PGIC.

The study explicitly reported no adverse events with TENS.
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TENS versus cervical mobilisation versus exercise

TENS versus acupuncture

We found one study comparing TENS versus cervical mobilisation
versus exercise (Prabhakar 2011).

We found one study comparing TENS with acupuncture (Rutgers
1988).

Primary outcomes

Primary outcomes

Change in pain intensity
Prabhakar 2011 investigated TENS versus cervical mobilisation
versus exercise in participants with cervical radiculopathy. Pain intensity at baseline was not presented or compared between groups.
Pain intensity (VAS 0-10) data at three weeks were presented as
reduction from baseline and VAS data at six weeks were not supplied. The VAS pain outcomes at three weeks were: reduction from
baseline (mean ± SD): -3.53 ± 0.76 with TENS, -4.49 ± 0.76
with mobilisation, -2.16 ± 0.8 with isometric exercise. The results
were presented as a series of within-group analyses. Between-group
testing was reported as significant; however, it is unclear if this
related to VAS pain intensity data and no data were reported for
this analysis. We did not undertake any further analysis of the data
in the absence of baseline data and sample sizes. We contacted the
authors repeatedly for clarification with no reply.
One study provided very low quality evidence (downgraded for
limitations of study, inconsistency and imprecision) investigating
cervical spine mobilisation, TENS and isometric exercise treatment for pain in participants with cervical radiculopathy. Despite
reporting significant differences between groups, it was impossible
to draw conclusions on relative efficacy of each intervention due
to lack of data and lack of information on statistical testing.

Change in pain intensity
Rutgers 1988 investigated TENS versus acupuncture in participants with PHN. The study reported no pain intensity data and
undertook no comparisons/analyses. This may be due to the very
high attrition rates; at nine weeks, three out of 13 in the TENS
group and five out of 10 participants in the acupuncture group
remained in the study. At nine weeks, one participant in the TENS
group reported a subjective improvement in pain intensity and
two participants in the acupuncture group reported moderate subjective improvement. No further analysis of this study was undertaken.
One study (very low quality evidence, downgraded for limitations
of study, inconsistency and imprecision) investigated TENS versus
acupuncture for pain in participants with PHN. It was impossible
to draw conclusions on relative efficacy of each intervention due to
significant methodological limitations and incomplete reporting
of data.

Changes in health related quality of life
The study did not report HRQoL.

Secondary outcomes

Changes in health related quality of life
The study did not report HRQoL.

Changes in participant global impression of change
The study did not report PGIC.

Secondary outcomes

Change in analgesic medication use
The study did not report drug use.
Changes in participant global impression of change
The study did not report PGIC.

Incidence/nature of adverse events
The study did not report adverse events.

Change in analgesic medication use
The study did not report drug use.

TENS versus exercise versus pharmacological therapy

Incidence/nature of adverse events

We found one study comparing exercise plus pharmacological
therapy versus TENS plus pharmacological therapy versus pharmacological therapy alone for pain in participants with diabetic
peripheral neuropathy (Serry 2015).

The study did not report adverse events.
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Primary outcomes

Change in pain intensity
The study reported pain intensity (VAS 0-10) changes using a
within-group analysis. Despite stating using between-group tests
there was no reporting of this. Within-group pain intensity percentage changes (comparing pretreatment to post-treatment) were
as follows: -41.67% with TENS plus pharmacological therapy,
-16.7% with exercise plus pharmacological therapy. The study reported no within-group statistical difference for the pharmacological therapy group. Neither baseline nor post-treatment assessment
points had any pain intensity data reported. We did not undertake
any further analysis in the absence of useable data. We attempted
to contact the authors on a number of occasions with no reply.
One study (very low quality evidence, downgraded for limitations of study, inconsistency and imprecision) investigated TENS
plus pharmacological therapy versus exercise plus pharmacological therapy versus plus pharmacological therapy alone for pain in
participants with PDN. Despite reporting significant differences
between groups, it was impossible to draw conclusions on relative
efficacy of each intervention due to lack of data and lack of information on statistical testing.

Primary outcomes

Change in pain intensity
Tilak 2016 investigated TENS versus mirror therapy in participants with phantom limb pain. The VAS scores were analysed using ’within’ and ’between’ group analysis. The study reported significantly different within-group changes in pain intensity (VAS
0-10) while between-group testing was not. Post-treatment pain
intensity VAS values at day four were (mean ± SD): 2.46 ± 1.56
with TENS, 2.08 ± 1.62 with mirror therapy, which represents
an MD of -0.38 (95% CI -0.8 to 1.6, P = 0.5) comparing mirror
therapy to TENS and confirms the lack of significant difference
between groups.
There was very low quality evidence (downgraded for limitations
of study, inconsistency and imprecision) that mirror therapy was
no more effective than TENS for treatment of pain at short-term
postintervention follow-up in participants with phantom limb
pain.

Changes in health related quality of life
The study did not report HRQoL.

Secondary outcomes

Changes in health related quality of life
The study did not report HRQoL.

Changes in participant global impression of change
The study did not report PGIC.

Secondary outcomes

Change in analgesic medication use
The study did not report drug use.
Changes in participant global impression of change
The study did not report PGIC.

Incidence/nature of adverse events
The study did not report adverse events.

Change in analgesic medication use
The study did not report drug use.

DISCUSSION

Incidence/nature of adverse events

Summary of main results

The study did not report adverse events.

We were unable to confidently state whether TENS is effective
(compare to sham TENS) for pain relief in people with neuropathic pain. The evidence we used in this comparison was very
low quality and the true effect is very likely to be substantially
different from that reported. The ’very low’ GRADE judgement
was based on the significant methodological limitations of the included studies, and overall small study sizes.

TENS versus mirror therapy
We found one study comparing TENS versus mirror therapy (
Tilak 2016).
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One study provided very low quality evidence that laser was more
effective than TENS when treating pain in participants with carpal
tunnel syndrome (Casale 2013). While the magnitude of the effect
size in this comparison may be considered meaningful, the design
of the study was such that allocation and blinding domains in risk
of bias assessment were unclear, which, when considered with the
small size of the study, necessitates limited confidence in this effect
size.
Very low quality evidence investigating TENS versus pharmacotherapy for pain in participants with PHN may be interpreted
as favouring carbamazepine plus clomipramine treatment (Gerson
1977). However, serious limitations in methodology and potential
bias means this result should be viewed with very limited confidence.
Two studies (very low quality evidence) investigated the efficacy of
TENS versus other electrotherapeutic modalities, PENS in participants with radicular pain secondary to sciatica (Ghoname 1999)
and IFT in participants with carpal tunnel syndrome (Koca 2014).
Significant concerns with the invasive nature of the PENS intervention and sham PENS intervention (Ghoname 1999), issues
with participant selection/allocation (Koca 2014). risk of bias and
participant/personnel blinding (Ghoname 1999; Koca 2014) rendered the results very limited in terms of confidence of the reported effects.
One study compared TENS versus PRF sympathectomy for pain
intensity in participants with PDN (Nabi 2015). This study did
not report variance of the data in the measured outcome and statistical tests did not appear to examine between-group differences.
There were also significant differences in final outcome measurement between groups and issues with participant/personnel blinding. We rated this study as providing very low quality evidence and
it was impossible to draw conclusions on relative effectiveness.
Two studies investigated aspects of visual manipulation versus
TENS on pain intensity ( zkul 2015; Tilak 2016). Comparisons
were VI versus TENS in participants with spinal cord injury ( zkul
2015), and mirror therapy versus TENS in participants with phantom limb pain (Tilak 2016). Upon completion of treatment, there
was no significant difference in pain intensity measures between
groups in either study. Evidence provided by these studies was
rated very low quality. The results should be viewed with limited
confidence.
One study investigated cervical spinal joint mobilisation versus
TENS versus isometric exercises for pain in participants with cervical radiculopathy (Prabhakar 2011). However, significant issues
with methodology/potential risk of bias and data presentation/
analysis in this paper meant it was impossible to draw conclusions
regarding relative effectiveness of the investigated interventions.
One study investigated TENS versus acupuncture in participants with PHN (Rutgers 1988). This study had very significant
methodological issues including high risk of bias across multiple
domains, lack of published useable data and no statistical analysis;
therefore, we were unable to draw conclusions regarding relative

effectiveness of the investigated interventions.
One study investigated exercise plus pharmacotherapy versus
TENS plus pharmacotherapy versus pharmacotherapy alone for
pain in participants with diabetic peripheral neuropathy (Serry
2015). This study reported significant differences pretreatment to
post-treatment in exercise and TENS groups; however, they reported no between-group comparison or presented any pain intensity data. This, combined with issues around participant/personnel blinding, meant we were unable to draw conclusions regarding relative effectiveness of the investigated interventions.

Overall completeness and applicability of
evidence
This review included studies investigating TENS treatment for
pain across a range of neuropathic conditions and against a number of interventions. We searched multiple databases for both published and unpublished studies. As such, it may be viewed as offering a reasonably complete summation of the evidence in this
area. However, there are a number of issues and caveats to consider which may impact on completeness and applicability of the
evidence.
Thirteen of the 15 studies in this review applied TENS interventions only in the clinic. This typically consisted of discreet sessions
at varying intervals per week for set periods of time applied by and
under control of the researcher. This may be due to methodological considerations and most likely addresses attempts to standardise the intervention, however, this is unlikely to be reflective of the
manner in which TENS is used by people in daily life. Evidence
suggests considerable variability in terms of treatment fidelity (e.g.
duration and intensity) when TENS is self-administered at home
(Pallett 2014). Therefore, controlled prespecified frequency and
duration of treatment may lead to discrepancies in estimate of effect (possible overestimation) compared to that found with selfadministered TENS. Conversely, it is possible that this issue might
lead studies in this review to underestimate treatment effects as it
limits the amount of TENS use possible. It is considered that successful TENS use is often administered for a number of hours per
day (Johnson 1991; Johnson 2011). Only one study in this review
employed a systematically evaluated self-administration methodology (Buchmuller 2012), implying that the relatively infrequent
and limited duration of clinic-administered TENS applications of
the rest of the studies in this review might lead to underestimation
of TENS effect.
The pooled analysis investigating TENS versus sham TENS rests
on the presumption that sham TENS is an effective placebo. However, there are challenges to delivering credible sham treatments
for TENS (see How the intervention might work). This further
reduces the confidence with which the estimated effect of active
TENS versus sham TENS may be viewed. There are devices specifically designed to be a credible TENS sham which switch on, appear ’live’ and deliver a perceptible sensation for approximately
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the first 30 seconds after which the output fades to zero (Rakel
2010). However, since clear differences in the experience of TENS
and sham TENS are unavoidable, the risk of bias in terms of incomplete blinding remains an issue. This raises the prospect that
pragmatic comparisons such as TENS in addition to usual care
may be appropriate.
This review included studies with varying timing of assessment
outcome for pain. None of the included studies in this review providing useable data employed a methodology whereby effect on
pain intensity was assessed and reported on during TENS application which may impact on effect estimates. It is suggested that
TENS has its optimal effect during application (Johnson 2011;
Sluka 2013). Again, this may create some discrepancy between
study findings and the experience of people with neuropathic pain
who use or plan to use TENS.
This review excluded a number of studies as they did not fit our
prespecified inclusion criteria. Several of these studies were excluded on the basis of using composite assessment scales which
combined pain assessment with other features (e.g. pain intensity, paraesthesia and sleep disturbance) assessed on one symptom
scale. While we deemed this critical in being able to successfully
extract data and draw conclusions on TENS for treatment of pain
in people with neuropathic pain, it does leave the possibility that
this review may miss other non-pain specific effects of TENS in
people with neuropathic pain and ultimately that this review may
not synthesise the entirety of studies conducted in the broad area
of TENS for neuropathic pain.

Quality of the evidence
We rated the overall quality of the body of evidence as very low
according to GRADE criteria. As a consequence, the conclusions
drawn from pooled estimates and those taken from individual
studies must be viewed with very limited confidence and the true
effect is likely to be substantially different from the estimate of the
effect. All studies were at unclear or high risk of bias across multiple
domains. Within the 10 studies reported narratively, seven were
assigned high risk across at least one of the key domains of selection
bias: performance bias, detection bias, attrition bias or reporting
bias (Gerson 1977; Ghoname 1999; Koca 2014; Nabi 2015;
Prabhakar 2011; Rutgers 1988; Serry 2015).
In the pooled analysis, we assigned all studies as high risk across
at least one of the key domains of selection bias mentioned above.
When considering the combined high risk ratings in these domains, the possible bias introduced by small study sizes and the
subjective nature of the outcome measure it would suggest the
effect sizes estimated here are at risk of being exaggerated, particularly given the subjective nature of the outcome measure
(Dechartres 2013; Wood 2008; Savovi 2012). As a consequence,
we downgraded the quality of the body of this evidence three times
(twice for methodological limitations and once imprecision) from
high to very low.

We did not downgrade the evidence on the GRADE criteria ’indirectness’ or ’publication bias.’ All included studies investigated
either participants with neuropathic pain directly or were able to
provide data for subsets of the group with neuropathic pain. The
prevalence of small studies, as mentioned previously, increases the
risk of publication bias, wherein there is a propensity for small negative studies to not reach full publication. There is evidence that
this might lead to an exaggerated estimate of effect (Dechartres
2013; Moore 2012; Nüesch 2010). We did not downgrade any
of the GRADE judgements on the basis of publication bias as we
had no direct evidence of this, though all comparisons were downgraded for imprecision.
Overall across studies, we found deficiencies in terms of quality of
methodology, reporting of methodology and presentation of adequate data to allow reasonable conclusions to be made. A number
of studies did not report data on pain outcome measures, instead
stating significant differences between groups with no data provided or statistical test results. Some studies did not report variance data for group means (VAS) and one study did not report
group sample size. It was not always possible to check baseline
characteristics of groups as pain intensity data (in some studies)
were presented as change from baseline with no original baseline
summary/variance data provided. Several studies did not report
adequately on TENS treatment parameters.

Potential biases in the review process
This review utilised a comprehensive search strategy designed and
implemented under expert guidance from the Cochrane Pain, Palliative and Supportive Care Review Group. It was deployed across
multiple databases and language of publication was not restricted.
Given the rigour of the searches conducted it seems reasonable
to assert this review reflects the current body of literature around
treatment of pain with TENS in people with neuropathic pain.
While review authors were not blind to study authors, journal or
institution, we performed all eligibility assessment independently
and comparisons for inclusion made by discussion and agreement.
Change in pain intensity measured via a VAS or NRS was a key
eligibility criterion for this review. Several studies utilised composite neuropathic assessment scales that did not allow pain intensity
data to be presented as a distinct outcome. Similarly, we excluded
studies in which a defined neuropathic pain subgroup could not
be delineated. For example, TENS has been investigated for treatment of low back pain in people with multiple sclerosis, however,
this may not be neuropathic in nature. These two aspects of study
inclusion/exclusion judgement may introduce an element of bias
into the review process in that the reported effect estimate may
not be fully reflective of all studies in this broad area. However,
given the widespread use of TENS as a pain treatment, it was
deemed important by the review team that the effect reported was
restricted to distinct measures of pain intensity in participants with
defined neuropathic pain. Representing mean change scores on
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continuous scales can be seen as problematic in chronic pain studies since outcomes in pain studies demonstrate a bimodal distribution for some interventions (Moore 2013). More plainly, some
participants demonstrated a substantial response to pain therapies
while many demonstrated little or no response with few individual
participants demonstrating a response similar to the average. This
had led to the recommendation that chronic pain studies employ
responder analysis based on predetermined cut-offs for a clinically
important response (30% reduction in pain or greater for a moderate benefit, 50% reduction in pain or greater for a substantial
benefit) (Dworkin 2008; Moore 2010). No studies identified in
this review presented the results of responder analyses and so this
type of meta-analysis was impossible. However, it is unclear if a
bimodal distribution of outcome represents a bimodal distribution of treatment effect and we are not aware of any evidence to
support the presence of bimodally distributed outcomes following
TENS.

Agreements and disagreements with other
studies or reviews
Due to the very low quality evidence, this Cochrane systematic
review was unable to confidently state whether TENS is effective for pain relief compared to sham TENS in people with neuropathic pain. Two reviews investigating treatment modalities in
people with neuropathic pain have been published. Cakici 2016
conducted a broad based review investigating all treatment options
for people with peripheral diabetic neuropathy and included one
study involving TENS and restricted outcomes to commentary in
that it was deemed to have a ’positive’ effect on symptoms. The
second review investigated 22 common treatments for people with
spinal cord injury (Harvey 2016). The two TENS comparison
studies included in this review were also included in our review (Bi
2015; Celik 2013). In line with our finding, the review presented
a meta-analysis in favour of TENS as well as similar commentary
around quality of evidence.

AUTHORS’ CONCLUSIONS
Implications for practice
For people with neuropathic pain
This review presents very low quality evidence and cannot confidently state whether transcutaneous electrical nerve stimulation
(TENS) is effective for pain relief compared to sham TENS in
people with neuropathic pain. We have very limited confidence
in this estimate of effect given the identified quality issues in the
published evidence. People with neuropathic pain should bear in

mind the low number of studies, the low quality of this evidence
and the fact that the true effect is very likely to be different from
that reported here when considering whether or not to use TENS
for pain. We are unable to make any judgement on the effect of
TENS on health related quality of life, global impression of change
or medication use. Some studies reported minor skin irritation
with TENS while others reported no adverse events. The majority
did not report adverse events and we are, therefore, unable to make
meaningful comment on TENS and associated adverse events.

For clinicians
This review is unable to state the effect of TENS versus sham
TENS for pain relief due to the very low quality of the included
evidence. The low number and small size of included studies and
very low quality of the evidence means this result should be viewed
with very limited confidence and the true effect is very likely different from that reported here. A small number of studies reported
only minor adverse events (skin irritation). The majority of studies did not provide any detail on the safety profile of TENS; this
should be explicitly addressed in future studies.

For policy makers and funders
This review neither refutes nor supports the use of TENS in management of neuropathic pain. The results reported here reflect
short-term outcome assessment only, are derived from studies that
have substantial methodological limitations and may not be reflective of how TENS is typically used by people with pain.

Implications for research

General
TENS is a portable, easily administered modality which is accessed
and used by people with pain as required. It is recommended
that future studies reflect this (i.e. TENS should be self-administered by the person and investigated in this manner). Blinding
in physical interventions such as TENS is challenging. If sham
TENS studies are used, at the least the sham TENS devices should
be identical and appear ’active’ in an effort to maintain the perception of treatment validity. Efforts should be made to preserve
the naivety of the participant to the intervention and treatment
providers/assessors should be blinded to group allocation. Studies
in which participants self-administer the intervention would be
very helpful in improving this aspect of future TENS research.
Consideration may be given to further studies assessing optimal
care versus optimal care plus active TENS as an acknowledgment
that sham TENS methodologies may be inherently flawed.
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Design
Improved quality in study design and reporting would significantly
add to the confidence in our estimates of effectiveness. Future studies should consider the IMMPACT recommendations for the design of studies in chronic pain to ensure that outcomes, thresholds
for clinical importance and study designs are optimal (Dworkin
2008; Dworkin 2009; Dworkin 2010; Turk 2008). Clear guidance on study design is provided by the CONSORT statement
and subsequent checklist (Schulz 2010). Integral to this should
be the requirement for clearly defined neuropathic pain participants with suitable diagnostic criteria required for inclusion. Interventions should be clearly described and we recommend active
TENS treatments should be of sufficient intensity to be perceived
as ’strong’ with participants titrating intensity to maintain this
perception throughout the duration of treatment (Johnson 2011;
Moran 2011; Sluka 2013). A recurring feature across reporting of
studies in this field was lack of published outcome data. We would
strongly recommend all primary specified outcomes be reported
in summary form for all comparison groups (mean/median and
standard deviation/range/interquartile ranges) at baseline and all
assessment times postrandomisation. This would greatly aid future assessment of effect via systematic review of studies.

term effects. Possible pain reducing effect of TENS may allow
changes in function and self-efficacy which in turn may influence
overall longer term perception of pain. It should be noted though
that the relationship between efficacy of interventions on pain and
disability in people with chronic pain is likely complex and not
predictable (Saragiotto 2017). Valid measures of function/quality
of life should also be key reportable outcome measures along with
pain intensity in future TENS studies.
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CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]
Barbarisi 2010
Methods

RCT, parallel design.

Participants

30 participants with postherpetic neuralgia, divided into 2 groups initially TENS (n =
16) and sham (n = 14). Each group further subdivided by concurrent dose of pregabalin.
TENS group (pregabalin 300 mg, n = 9; pregabalin 600 mg, n = 7). Sham group
(pregabalin 300 mg, n = 8; pregabalin 600 mg, n = 6). Baseline participant characteristics
presented by gender not group
Age (mean ± SD): men 65 ± 8.6 years; women 64 ± 8.2 years.
Pain duration: men 15.6 ± 8.8 months;
women: 14.9 ± 8.6 months.
Formal neuropathic pain assessment: no.
Sites of pain: left hemithorax: men 9, women 10; right hemithorax: men 3, women 4;
leg: men 4, women 2; arm/forearm: men 4, women 4
Concomitant treatment: all participants received pregabalin (300 mg or 600 mg) over
initial 8 days’ treatment until a pain intensity VAS of ≤ 60 mm was achieved. Following
this, participants were randomised to TENS or sham. TENS/sham treatment continued
for 4 weeks following randomisation. All participants continued with pregabalin treatment during the TENS/sham phase

Interventions

TENS group: TENS 100 Hz (inconsistent description in text, later described as 50 Hz)
, 125 µs
Intensity: “Clear non-painful paraesthesia.”
Sham TENS group: as per active TENS but no current passed through electrodes
Sham credibility assessment: no.
Location: electrodes placed around site of pain.
Frequency of treatment: daily for 4 weeks.
Duration: 30 minutes per session.
Clinic administered.

Outcomes

Daily pain intensity.
0-10 cm VAS.
Outcomes measured daily pretreatment and post-treatment. VAS comparisons presented
between baseline (day of randomisation to VAS group), week 3 and final VAS (posttreatment completion - week 4)
Did not report adverse events.

Notes

There may be mistakes in text of the article. VAS comparisons presented at ’week 3’ and
’final’ (week 4). It may be ’week 3’ comparison is in fact ’week 4’. No conflict of interest
stated

Risk of bias
Bias

Authors’ judgement

Support for judgement
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Barbarisi 2010

(Continued)

Random sequence generation (selection Low risk
bias)

Computer generated randomisation.

Allocation concealment (selection bias)

Allocation concealment not reported.

Unclear risk

Blinding of participants and personnel High risk
(performance bias)
All outcomes

Unclear risk for blinding of participants (TENS vs sham, attempted to manage participant expectations of sensation but no
detail on whether TENS device appeared ’live’ or not). Personnel high risk as the same care provider applied both active and
sham treatments

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

TENS vs active sham but see comments above for blinding of
participants

Incomplete outcome data (attrition bias)
All outcomes

No participant dropout after TENS group randomisation. No
details regarding dropout during drug titration phase

Low risk

Incomplete outcome data (participant ex- Low risk
clusion from analysis)

No obvious exclusions and dropouts data described.

Selective reporting (reporting bias)

Unclear risk

Inconsistencies in data presentation. VAS pain data presented in
text for week 3 post-randomisation while data in tables presented
for final (week 4) VAS

Other bias

Unclear risk

Baseline characteristics presented by gender not group characteristics

Size of study

High risk

TENS group: n = 16; sham TENS group: n = 14.

Bi 2015
Methods

RCT, parallel design.

Participants

52 participants with spinal cord injury. 4 dropouts, 2 per group. TENS: 17 men, 7
women; sham TENS
15 men, 9 women.
Age (mean ± SD): TENS 35 ± 9 years; sham TENS 33.6 ± 8.5 years
Time since spinal cord injury (mean ± SD): TENS 7 ± 4.1 months; sham TENS 6.8 ±
3.1 months
Formal neuropathic pain assessment: no.
Sites of pain: mixed.
Concomitant treatment: no details supplied.

Interventions

TENS group: TENS 2 Hz, 200 ms.
Intensity: 50 mA. No description of perceived sensation.
Sham TENS group: as per active TENS but no current passed through electrodes
Sham credibility assessment: no.
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Bi 2015

(Continued)
Location: electrodes placed on region with pain.
Frequency of treatment: 3 times per week for 12 weeks.
Duration: 20 minutes per session.
Clinic administered.

Outcomes

Current pain intensity.
0-10 cm VAS.
Outcomes measured at baseline (pretreatment) and immediately post-treatment at 12
weeks
Study did not report adverse events.

Notes

No conflict of interest stated.

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Computer generated random number sequence.

Allocation concealment (selection bias)

Allocation concealment not reported.

Unclear risk

Blinding of participants and personnel High risk
(performance bias)
All outcomes

Unclear risk for blinding of participants (sham control but no
attempt to manage participant expectations of sensation and no
detail on whether TENS device appeared ’live’ or not). Personnel
high risk as the same care provider applied both active and sham
treatments

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

TENS vs active sham but see comments above for blinding of
participants

Incomplete outcome data (attrition bias)
All outcomes

Approximately 4% dropout balanced between groups.

Low risk

Incomplete outcome data (participant ex- Low risk
clusion from analysis)

No obvious exclusions and dropout data adequately described.

Selective reporting (reporting bias)

Low risk

All outcomes adequately reported

Other bias

Low risk

Baseline characteristics comparable, outcome assessment times
equal

Size of study

High risk

n = 24 per group.
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Buchmuller 2012
Methods

RCT, parallel design.

Participants

236 participants divided into TENS group: 45 men, 72 women, sham TENS group: 43
men, 76 women, Neuropathic (radicular pain) subgroup n = 139. Of this neuropathic
group, VAS pain intensity data provided by authors for radicular pain at baseline and
post-treatment for 122 participants (TENS group n = 64, sham TENS group n = 58).
At 3 months, 38% dropout with TENS group n = 43, sham TENS group n = 32
Age (mean ± SD): TENS group 52.0 ± 13 years for whole group. No data reported for
neuropathic subgroup; sham TENS group 53.4 ± 12.9 years for whole group. No data
reported for neuropathic subgroup
Unable to determine duration of pain for neuropathic subgroup
Formal neuropathic pain assessment: clinical assessment and DN4 ≥ 4
Sites of pain: lower limb (radicular pain subgroup).
Concomitant treatment: no details supplied for neuropathic subgroup

Interventions

TENS group: TENS mixed, 80-100 alternated with 2 Hz, 200 ms.
Intensity: alternating low intensity paraesthesia with high intensity perceived sensation
including muscle twitches
S ham TENS group: as per active TENS but no current passed through electrodes
Sham credibility assessment: no.
Location: 2 electrodes placed in low back area and 2 electrodes on radicular region
Frequency of treatment: 4 treatment sessions per day for 3 months
Duration: 1 hour per session.
Self-administered.

Outcomes

Primary outcome: RDQ.
Secondary outcomes: pain and quality of life (SF-36). Neuropathic subgroup outcomes
reported as Pain reduction (3 months) and RDQ (6 weeks). No separate SF-36 reported
for neuropathic subgroup
Pain recorded on 0-10 cm VAS. Pain intensity data at baseline and post-treatment supplied by authors for neuropathic group, specifically for the radicular pain component.
VAS scored as weekly mean measures
Outcomes measured at baseline (pretreatment) and immediately post-treatment at 12
weeks
Minor skin irritation in 14 participants.

Notes

Funding sources acknowledged and no conflict noted. Authors contacted with request
for detailed data on pain intensity outcome measures for neuropathic subgroup and
kindly provided these data

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Computer generated stratified randomisation.

Allocation concealment (selection bias)

Central allocation.

Low risk
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Buchmuller 2012

(Continued)

Blinding of participants and personnel Low risk
(performance bias)
All outcomes

Participants blind (TENS vs sham, attempts made to manage
participant expectations of sensation and the TENS device appeared ’live’) and treatment self-administered

Blinding of outcome assessment (detection Low risk
bias)
All outcomes

Participants blinded, sham vs active TENS.

Incomplete outcome data (attrition bias)
All outcomes

At 3 months, 47 participants were missing from the original
baseline data for participants with radicular pain. This represents
a 38.5% dropout

High risk

Incomplete outcome data (participant ex- Unclear risk
clusion from analysis)

No detail provided with respect to missing data and participant
exclusion from analysis

Selective reporting (reporting bias)

Unclear risk

Low risk for total study. Unable to assess for neuropathic subgroup and lack of SF-36 data for neuropathic subgroup

Other bias

Low risk

Baseline characteristics for total study well described.

Size of study

Unclear risk

Neuropathic subgroup: TENS group: n = 71; sham TENS
group: n = 68

Casale 2013
Methods

RCT, parallel design.

Participants

20 participants with carpal tunnel syndrome. TENS group: 5 women, 5 men; laser
group: 5 women, 5 men
Age (mean ± SD): TENS group: 56.8 ± 12 years; laser group: 57.3 ± 12.9 years
Duration of pain: no detail supplied.
Formal neuropathic pain assessment: nerve conduction study.
Sites of pain: hand.
Concomitant treatment: no details supplied.

Interventions

TENS group: TENS 100 Hz, 80 ms.
Intensity: “below muscle contraction,” no details on perceived sensation
Location: electrodes placed on carpal ligament and course of median nerve
Frequency of treatment: daily for 3 weeks, 15 sessions in total
Duration: 30 minutes per session.
Clinic administered.
Laser group: 250 J/cm2 25 W. Probe size 1 cm2 .
Location: 10 cm length along course of median nerve in wrist area
Frequency of treatment: daily for 3 weeks, 15 sessions in total
Duration: 100 seconds per session.
Clinic administered.

Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

Casale 2013

(Continued)

Outcomes

Pain intensity: no further detail.
0-10 cm VAS.
Outcomes measured at baseline (pretreatment) and post-treatment at 3 weeks
Study did not report adverse events.

Notes

No conflict of interest stated.

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Computer aided sequence generation.

Allocation concealment (selection bias)

No details supplied.

Unclear risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Both groups received an ’active’ treatment.

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Participants received active treatment in both groups.

Incomplete outcome data (attrition bias)
All outcomes

No dropouts reported.

Low risk

Incomplete outcome data (participant ex- Low risk
clusion from analysis)

No obvious exclusions from analysis.

Selective reporting (reporting bias)

Low risk

All stated outcomes reported.

Other bias

Low risk

Baseline characteristics between groups adequately tested and
described

Size of study

High risk

n = 10 per group.

Celik 2013
Methods

RCT, parallel design.

Participants

33 participants with spinal cord injury. No participant dropout reported. TENS 4 men,
13 women; sham TENS 11 men, 5 women
Age (mean ± SD): TENS group: 38.18 ± 9.86 years; sham TENS group: 34.81 ± 10.91
years
Mean duration of pain (range): 19.1 (1-170) months for whole sample. No further data
supplied
Formal neuropathic pain assessment: LANSS > 12.
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Celik 2013

(Continued)
Sites of pain: mixed; cervical and ’back’, thigh, knee and foot
Concomitant treatment: amitriptyline 10 mg both groups.

Interventions

TENS group: TENS 4 Hz, 200 µs.
Intensity: 50 mA. No description of perceived sensation.
Sham TENS group: as per active TENS but no current passed through electrodes
Sham credibility assessment: no.
Location: electrodes placed around region with pain.
Frequency of treatment: 1 application per day for 10 days.
Duration: 30 minutes per session.
Clinic administered.

Outcomes

Pain intensity mean of morning, noon, evening and night VAS scores
0-10 cm VAS.
Outcomes measured at baseline (pretreatment) on day 1 and 1 day following treatment
cessation (day 12)
Study reported adverse events and none occurred.

Notes

Baseline testing between group for difference in pain location, duration were reported
as not being significantly different but no data provided. No description of baseline
comparison for LANSS score. No conflict of interest stated

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection High risk
bias)

Alternate participant group allocation.

Allocation concealment (selection bias)

Alternate participant group allocation.

High risk

Blinding of participants and personnel High risk
(performance bias)
All outcomes

Low risk for blinding of participants (sham controlled study and
no sensation reported from either active or sham device given
participants had spinal cord injury). Personnel high risk as the
same care provider applied both active and sham treatments

Blinding of outcome assessment (detection Low risk
bias)
All outcomes

Participants blinded, sham vs active TENS.

Incomplete outcome data (attrition bias)
All outcomes

No dropout of participants.

Low risk

Incomplete outcome data (participant ex- Low risk
clusion from analysis)

No obvious exclusion from analysis.

Selective reporting (reporting bias)

All outcomes adequately reported.

Low risk
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Celik 2013

(Continued)

Other bias

Low risk

Baseline testing reported albeit without data presented for all
tests

Size of study

High risk

TENS group: n = 17; sham TENS group: n = 16.

Gerson 1977
Methods

Randomised parallel design.

Participants

29 participants with postherpetic neuralgia. TENS group (n = 16), drugs group (n = 13)
. No detail on gender across groups. n = 10 dropouts in TENS group and n = 7 dropout
in drugs group
No baseline characteristics supplied for either group.
Formal neuropathic pain assessment: no.
Sites of pain: no details.
Concomitant treatment: no details.

Interventions

TENS group: no detail supplied for TENS application parameters or participant perceived intensity
Location: ’Electrodes placed over the surface of the affected dermatome.’
Frequency of treatment: 1 TENS treatment session per week for 4 weeks then 1 treatment
applied every second week for 3 weeks
Duration: 15 minutes per session.
Clinic administered.
Drug group: carbamazepine plus clomipramine. No further detail supplied on dosage
Duration of treatment: 8 weeks.

Outcomes

Pain intensity at each visit.
0-10 cm VAS. No detail whether mean, current or maximal pain recorded at each visit
Outcomes measured at baseline (pretreatment) day 0 then at weeks 2, 4, 6 and 8
Study did not report adverse events.

Notes

Inconsistencies in text with respect to treatment protocol and duration. Data analysed
on per protocol basis. No conflict of interest stated

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

No detail supplied.

Allocation concealment (selection bias)

No detail supplied.

Unclear risk

Blinding of participants and personnel High risk
(performance bias)
All outcomes

Given discrepancy in treatment types and application.
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Gerson 1977

(Continued)

Blinding of outcome assessment (detection High risk
bias)
All outcomes

As above.

Incomplete outcome data (attrition bias)
All outcomes

Approximately 60% dropout.

High risk

Incomplete outcome data (participant ex- High risk
clusion from analysis)

Per protocol analysis.

Selective reporting (reporting bias)

High risk

No variance in reported TENS data. Follow-up data uninterpretable

Other bias

High risk

No baseline characteristics described.

Size of study

High risk

TENS group: n = 16; drug group: n = 13.

Ghoname 1999
Methods

3 phase cross-over study.

Participants

64 participants with lumbar radicular pain. 34 women and 30 men. No dropouts reported
over entire study. Participants randomised to 3 treatment sequences 1: sham, PENS,
TENS; 2: PENS, TENS, sham; and 3: TENS, sham, PENS
Age (mean ± SD): 43 ± 19 years (of the whole sample).
Duration of pain (mean ± SD): 21 ± 9 months.
Formal neuropathic pain assessment: pain radiating below knee, positive straight leg raise
testing. Radiological evidence of L5-S1 nerve root compression
Sites of pain: low back /leg, radicular pain.
Concomitant treatment: non-opioid analgesia.

Interventions

Treatment sequence 1: sham, PENS, TENS.
Treatment sequence 2: PENS, TENS, sham.
Treatment sequence 3: TENS, sham, PENS.
TENS treatment: TENS 4 Hz, 100 ms.
Intensity: maximum tolerated amplitude without producing muscle contraction
Location: 4 electrodes placed on posterior lower limb.
PENS treatment: 4 Hz, 100 ms.
Intensity: highest tolerable sensation without muscle contraction
Location: 10 × 32G acupuncture needles inserted into posterior lower limb
S ham PENS treatment: as per active PENS but no current passed through electrodes
Sham credibility assessment: no.
Frequency of treatment: 3 applications per week for 3 weeks. 1 week washout between
treatment modalities
Duration: 30 minutes per session.
Clinic administered.

Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

Ghoname 1999

(Continued)

Outcomes

Pain intensity recorded at each visit and 24 hours after last treatment of each modality.
Score reflected pain intensity during previous 24 hours. SF-36 completed at baseline and
24 hours after last treatment session of each modality. NSAID use reported as change
within modality
0-10 cm VAS for pain.
Study did not report adverse events.

Notes

SF-36 and NSAID use appears to have been taken at initial baseline and then 24 hours
following each treatment modality completion. No apparent testing for carry-over effects
on outcomes. Similar sham PENS was an invasive procedure compared to TENS. No
conflict of interest stated

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

No details supplied.

Allocation concealment (selection bias)

Cross-over design.

Low risk

Blinding of participants and personnel High risk
(performance bias)
All outcomes

Invasive vs non-invasive treatment modalities.

Blinding of outcome assessment (detection High risk
bias)
All outcomes

Invasive vs non-invasive treatment modalities.

Incomplete outcome data (attrition bias)
All outcomes

Missing data or dropouts not reported over the multiple
treatment contacts

Unclear risk

Incomplete outcome data (participant ex- Low risk
clusion from analysis)

Not applicable.

Selective reporting (reporting bias)

High risk

SF-36 data not adequately reported or tested.

Other bias

Unclear risk

No formal assessment of carry-over effects but data appeared
very similar at baseline

Size of study

Unclear risk

n = 64.
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Koca 2014
Methods

RCT, parallel.

Participants

75 participants with carpal tunnel syndrome equally to 3 treatment groups. 12 people
dropped out during/follow-up approximately evenly across groups. Splint group, 15
women, 7 men; TENS group 13 women, 7 men; IFT group 15 women, 6 men
Age (mean ± SD): splint group: 35.4 ± 4.2; TENS group: 34.2 ± 5.2; IFT group: 34.9
± 4.8 years
Mean duration of pain: splint group: 12.4 ± 6.2; TENS group: 13.5.2 ± 6.6; IFT group:
13.0 ± 6.0 months
Formal neuropathic pain assessment: positive nerve conduction studies
Sites of pain: hand.
Concomitant treatment: paracetamol as required daily.

Interventions

Splint group: wrist-hand resting splint at night for 3 weeks.
TENS group: TENS 100 Hz, 80 ms.
Intensity: no description of perceived sensation.
IFT group: 4000 Hz with base 20 Hz.
Intensity: no description of perceived sensation.
Location: electrodes for both modalities placed around palmar aspect of hand/wrist/
thenar area
Frequency of treatment: 5 times per week for 3 weeks.
Duration: 20 minutes per session.
Clinic administered.

Outcomes

Pain intensity: mean levels of pain in previous week.
0-10 cm VAS.
Outcomes measured at baseline and 3 weeks after completion of treatment (6 weeks after
randomisation)
2 participants in TENS group reported mild tenderness at application site

Notes

No conflicts of interest stated.

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection High risk
bias)

Sequential admission into study.

Allocation concealment (selection bias)

Sequential allocation.

High risk

Blinding of participants and personnel High risk
(performance bias)
All outcomes

Participant blinding was unclear if comparing TENS to IFT
but high when comparing TENS to splint therapy. Personnel
high risk as the same care provider applied both TENS and IFT
treatments

Blinding of outcome assessment (detection High risk
bias)
All outcomes

Participant blinding was unclear if comparing TENS to IFT
but high when comparing TENS to splint therapy. Personnel
high risk as the same care provider applied both TENS and IFT
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Koca 2014

(Continued)
treatments

Incomplete outcome data (attrition bias)
All outcomes

High risk

Participants lost to follow-up specifically excluded.

Incomplete outcome data (participant ex- High risk
clusion from analysis)

Participants excluded if they failed to take part in the treatment
regimen

Selective reporting (reporting bias)

Low risk

Stated outcomes adequately reported.

Other bias

Unclear risk

Baseline characteristics tested and reported.

Size of study

High risk

n = 75 randomised across 3 treatment groups.

Nabi 2015
Methods

RCT, parallel.

Participants

65 participants with diabetic neuropathy to 2 treatment groups, TENS and PRF sympathectomy. Overall, 10 participants (15%) described as having dropped out, however,
sample sizes for both groups were stated as n = 30 (29 women, 31 men). Unable to
accurately state gender composition of each group
Age (mean ± SD): TENS group: 56.63 ± 5.86 years; PRF sympathectomy group: 56.76
± 6.94 years
Mean duration of diabetes: TENS group: 12.56 ± 2.96; PRF sympathectomy group: 13.
32 ± 3.91
Formal neuropathic pain assessment: no - diagnosed by neurologist
Sites of pain: lower limb.
Concomitant treatment: pregabalin 300-600 mg.

Interventions

TENS group: TENS 80 Hz, appears to be 200 µs.
Intensity: ’two to three times sensory threshold.”
Location: electrodes placed around shin and ankle.
Frequency of treatment: 10 treatment sessions delivered on alternate days
Duration: 20 minutes per session.
Clinic administered.
PRF sympathectomy group: PRF sympathectomy delivered as one-off invasive intervention

Outcomes

Pain intensity: mean levels of pain in previous week.
0-10 cm NRS.
Outcomes measured at baseline, 1 week, 1 month and 3 months following cessation
of treatment (either one-off PRF sympathectomy or 10 sessions of TENS on alternate
days). Hence outcomes between groups were measured at differing time points postrandomisation
“Skin irritation reported in a few TENS group subjects.”

Notes

Supported by university funding.
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Nabi 2015

(Continued)

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

Block randomisation.

Allocation concealment (selection bias)

No detail supplied.

Unclear risk

Blinding of participants and personnel High risk
(performance bias)
All outcomes

Clearly different treatments and 1 invasive.

Blinding of outcome assessment (detection High risk
bias)
All outcomes

Impossible to blind given the protocol.

Incomplete outcome data (attrition bias)
All outcomes

Discrepancies in dropout and indicated analysis.

Unclear risk

Incomplete outcome data (participant ex- Unclear risk
clusion from analysis)

Analysis not fully described and inconsistencies in dropout description

Selective reporting (reporting bias)

Low risk

All outcomes reported.

Other bias

Unclear risk

Differences in time postrandomisation outcome measurement
between groups

Size of study

High risk

Reported as TENS group: n = 30; PRF sympathectomy group:
n = 30

Prabhakar 2011
Methods

RCT, parallel design.

Participants

75 participants with cervical radicular pain. No participant dropout reported. Randomised into 3 groups: joint mobilisation, TENS and isometric exercises. No details
supplied on individual group size or gender composition. Whole sample 48% women,
52% men. Between-group baseline tests for age, body mass and pain duration reported
as ”homogenous;’ no formal statistical testing
Age (mean ± SD): Group A: 36.33 ± 9.4 years; Group B: 37.25 ± 9 years; Group C: 39.
33 ± 8.6 years
Mean duration of pain: no data supplied.
Formal neuropathic pain assessment: no.
Sites of pain: cervical spine and unilateral upper limb pain
Concomitant treatment: heat packs applied to the cervical spine area
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Prabhakar 2011

(Continued)

Interventions

Joint mobilisation group: cervical spine lateral flexion joint mobilisation, 10 sessions
on alternate days over 3 weeks
TENS group: TENS 100 Hz, 50 µs. Intensity: no detail supplied, 10 sessions on alternate
days over 3 weeks, 30 minute per session. Electrodes placed at cervical spinal segment
and distal dermatomal area
Exercise group: isometric neck exercises: isometric flexion, lateral flexion, rotation and
extension. 6-8 seconds per contraction. 5 repetitions for each muscle group. No details
on intensity of contraction. 10 sessions on alternate days over 3 weeks
All treatments administered/supervised in clinic.

Outcomes

Pain intensity. No details on pain intensity instructions with respect to current pain,
mean pain, etc
0-10 cm VAS.
Outcomes measured at baseline (pretreatment) week 3 and week 6 (3 weeks post-treatment finished)
Study did not report adverse events.

Notes

Week 3 VAS results were reported as reduction from baseline. Unable to extract baseline
data. Week 6 data not reported in text. No conflict of interest stated

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

No details supplied.

Allocation concealment (selection bias)

No details supplied.

Unclear risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

2 active non-invasive treatments.

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

As above in terms of active treatments.

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

No details supplied.

Incomplete outcome data (participant ex- Unclear risk
clusion from analysis)

No details supplied.

Selective reporting (reporting bias)

High risk

Key baseline data and week 6 data not supplied.

Other bias

High risk

Baseline group characteristic testing not described. Age and pain
duration at baseline described as homogenous
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Prabhakar 2011

(Continued)

Size of study

High risk

Unknown sample size per group. Whole group: n = 75.

Rutgers 1988
Methods

Randomised parallel design.

Participants

26 participants with postherpetic neuralgia to 2 treatment groups: TENS group (n = 13)
and ACU group (n = 10). At 6 months, 13 dropouts in TENS group and 9 dropouts in
ACU group. Total sample = 13 women, 10 men
Age (median (range)): 73 (57-85) years.
Mean pain duration: 3 months to > 9 years.
Formal neuropathic pain assessment: no.
Sites of pain: mixed.
Concomitant treatment: no details supplied.

Interventions

TENS group: TENS 100 Hz, 200 µs.
Intensity: amplitude increased until ’a fairly strong sensation’ was perceived
Location: electrodes placed either side of painful area.
Frequency of treatment: 3 clinic administered 30 minute treatments in first week. Then
TENS unit loaned for home use for 5 weeks. No information regarding frequency of use
given for this period
ACU group: 2 treatment session per week for 6 weeks. Body and auricular stimulation.
Steel needles stimulated with current at 5-60 Hz
Duration: no details supplied.
Clinic administered.

Outcomes

Pain intensity, visual stepwise scale, 10 steps. Measured at intake, 6 weeks, 9 weeks and
6 months. No details supplied as to parameters of pain rating (current pain, mean pain,
etc.)
Study did not report adverse events.

Notes

No formal statistical tests employed. At 9 weeks, study had 7 participants left in study
(73% dropout). Private funding body acknowledged

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

No details supplied.

Allocation concealment (selection bias)

No details supplied.

Unclear risk

Blinding of participants and personnel High risk
(performance bias)
All outcomes

TENS vs invasive treatment.
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Rutgers 1988

(Continued)

Blinding of outcome assessment (detection High risk
bias)
All outcomes

Impossible due to treatments being compared.

Incomplete outcome data (attrition bias)
All outcomes

> 70% dropout at 9 weeks.

High risk

Incomplete outcome data (participant ex- High risk
clusion from analysis)

No final statistical tests performed but appears a per protocol approach

Selective reporting (reporting bias)

High risk

No data supplied for outcomes.

Other bias

Unclear risk

No baseline data supplied.

Size of study

High risk

TENS group: n = 10; ACU group: n = 13.

Serry 2015
Methods

Randomised parallel design.

Participants

60 participants with chronic DPN were randomised to 3 treatment groups: TENS group
n = 20, exercise group n = 20, pharmacological group n = 20. In the total sample, there
were 32 women and 28 men
Age (mean ± SD): TENS group: 51.6 ± 4.75 years; exercise group: 51.7 ± 4.44 years;
pharmacological group: 51.95 ± 4.38
Mean duration of DPN: TENS group: 12.05 ± 3.17; exercise group: 12.15 ± 0.38;
pharmacological: 12.3 ± 3.38 (unit of measurement not stated)
Formal neuropathic pain assessment: no, diagnosed clinically
Sites of pain: lower limb.
Concomitant treatment: all groups continued with “regular pharmacological therapy.”
There was no description of this for TENS and exercise group in either drugs or dosage.
However, the pharmacological group (regular therapy) was described as consisting of
“nerve growth stimulant; vitamin B complex and oral hypoglycaemic drugs or insulin.”
No further details or comparisons made between groups in this area

Interventions

TENS group: TENS 15 Hz, 250 µs.
Intensity: increased until “strong rhythmic muscle contractions” observed
Location: 2 electrodes placed bilaterally on lower aspect of medial tibial condyle and
superior to medial malleolus
Frequency of treatment: 3 days per week for 8 weeks.
Duration: 30 minutes per session.
TENS treatment clinic administered.
Exercise group: aerobic exercise on stationary bicycle.
Intensity: following warm-up, participants exercised at 50-70% of maximal heart rate
Frequency of treatment: 3 days per week for 8 weeks.
Duration: 50 minutes per session (5 minutes’ warm-up, 40 minutes’ exercise, 5 minutes’
cool down)
Pharmacological group: “regular therapy.” No further information supplied.
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Serry 2015

(Continued)

Outcomes

Pain intensity recorded pretreatment and post-treatment on a 0-10 VAS. No detail
supplied with respect to parameter measured with VAS (e.g. mean pain, minimal pain,
maximal pain, etc.). Nerve conduction studies of medial plantar sensory nerve performed
pretreatment and post-treatment
Study did not report adverse events.

Notes

Data not supplied for concomitant drug treatment. No data supplied for baseline or
post-treatment pain intensity scores. Paper stated Kruskal-Wallis testing was used to
assess between-group differences in pain intensity scores post-treatment; however, this
analysis was not reported. All significant pain intensity findings are based on within-group
analysis and no detail on output of these tests supplied. Pain intensity only presented
in descriptive form; percentage change from baseline. Have contacted authors regarding
pain intensity data
No conflict of interest reported.

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Unclear risk
bias)

No information supplied.

Allocation concealment (selection bias)

No information supplied.

Unclear risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Both interventions were active treatments.

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Self-reported VAS pain intensity data.

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

No information supplied.

Incomplete outcome data (participant ex- Unclear risk
clusion from analysis)

No information supplied.

Selective reporting (reporting bias)

High risk

No data on primary outcome of study. No data on concomitant drug treatment

Other bias

Unclear risk

No baseline comparison on pain intensity scores.

Size of study

High risk

n = 20 per group.
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Tilak 2016
Methods

RCT, parallel.

Participants

26 participants with phantom limb pain to 2 groups. TENS group: 11 men, 2 women,
1 dropout therefore n = 12; mirror group: 12 men, 1 female, n = 13
Age (mean ± SD): TENS group: 36.38 ± 9.55 years; mirror group: 42.62 ± 10.69 years
Amputations: TENS group: 3 upper and 10 lower limb amputations; mirror group: 4
upper and 9 lower limb amputations
Onset of phantom limb pain from date of surgery: TENS group: 13 ± 1.6 days; mirror
group: 13 ± 1.4 days
Formal neuropathic pain assessment: no.
Sites of pain: upper and lower limb.
Concomitant treatment: no detail supplied.

Interventions

TENS group: no TENS frequency details supplied.
Intensity: “strong but comfortable” without visible muscle contraction
Location: electrodes placed at site of pain on contralateral limb
Frequency of treatment: 1 session per day for 4 days.
Duration: 20 minutes per session.
Clinic administered.
Mirror group: intact limb movements performed with mirror.
Frequency: 1 session per day for 4 days.
Duration: 20 minutes per session.
Clinic administered.

Outcomes

Pain intensity: no details supplied as to parameters of pain rating (current pain, mean
pain, etc.)
0-10 cm VAS.
Outcomes measured at baseline and 4 days later.
Study did not report adverse events.

Notes

Funding from higher education institution acknowledged.

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Computer generated sequence.

Allocation concealment (selection bias)

Opaque sealed envelopes.

Low risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Both interventions active treatments.

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

Both interventions active treatments.
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Tilak 2016

(Continued)

Incomplete outcome data (attrition bias)
All outcomes

Low risk

1 participant dropout adequately described.

Incomplete outcome data (participant ex- Low risk
clusion from analysis)

Dropout minimal. All participants analysed.

Selective reporting (reporting bias)

Low risk

All outcomes reported.

Other bias

Low risk

Adequate description and testing of baseline characteristics

Size of study

High risk

TENS group: n = 12; mirror group: n = 13.

Vitalii 2014
Methods

RCT, parallel.

Participants

25 participants with spinal cord injury. 4 participants dropped out. No details on group
allocation given. TENS group: 10 men, 1 woman; sham TENS: 9 men, 1 woman
Age (mean ± SD): TENS group: 31.72 ± 7.7 years; sham TENS group: 28.9 ± 6.1 years
Duration of pain (mean (range)): 12.7 (0.5-14) months for whole sample. No further
data supplied
Formal neuropathic pain assessment: LANSS > 12; mean (range) score 15.95 (13-20)
Sites of pain: mixed.
Concomitant treatment: gabapentin started day 1 and increased in 300 mg increments
daily to basic dose of 900 mg/day by day 3

Interventions

TENS group: TENS 4 Hz, 200 ms.
Intensity: 50 mA. No description of perceived sensation.
Sham TENS group: as per active TENS but no current passed through electrodes
Sham credibility assessment: no.
Location: electrodes proximal and distal to region with pain
Frequency of treatment: 1 application per day for 10 days.
Duration: 30 minutes per session.
Clinic administered.

Outcomes

Pain intensity mean of morning and evening. Mean of these two scores at day 0 and day
10 used in analysis
0-10 cm VAS.
Outcomes measured at baseline (pretreatment) on day 0 and day 10 of the study
Study reported adverse events and none occurred.

Notes

No conflict of interest stated.

Risk of bias
Bias

Authors’ judgement

Support for judgement
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Vitalii 2014

(Continued)

Random sequence generation (selection Unclear risk
bias)

No details supplied.

Allocation concealment (selection bias)

No details supplied.

Unclear risk

Blinding of participants and personnel High risk
(performance bias)
All outcomes

Unclear risk for blinding of participants (TENS vs sham but no
attempt to manage participant expectations of sensation and no
detail on whether TENS device appeared ’live’ or not). Personnel
high risk as the same care provider applied active and sham
treatments

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

TENS vs active sham but see comments above for blinding of
participants

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

16% dropout rate. No information given with regards to group
allocation

Incomplete outcome data (participant ex- Unclear risk
clusion from analysis)

No obvious exclusion from analysis; however, dropout rate not
fully described with respect to group allocation

Selective reporting (reporting bias)

Low risk

All outcomes adequately reported.

Other bias

Low risk

Baseline testing reported albeit without data presented for all
tests

Size of study

High risk

TENS group: n = 11; sham TENS group: n = 10.

zkul 2015
Methods

Randomised cross-over design.

Participants

26 participants with spinal cord injury to 2 treatment groups: 1. VI followed by TENS;
2. TENS followed by VI. n = 12 per group (2 participants dropped out). Total sample:
6 women, 18 men
Age (mean ± SD): 32.33 ± 12.97 years.
Mean pain duration: 12.46 ± 17.83 months.
Formal neuropathic pain assessment: ≥ 4 on DN4.
Sites of pain: at or below level of spinal cord injury.
Concomitant treatment: pregabalin 300-600 mg.

Interventions

TENS treatment: TENS 80 Hz, 180 µs.
Intensity: perceptible but not uncomfortable.
Location: electrodes placed bilateral spinal region above level of injury
Frequency of treatment: 5 days per week for 2 weeks.
Duration: 30 minutes per session.
VI treatment: 20 minutes of VI treadmill walking.
Frequency of treatment: 5 days per week for 2 weeks.
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zkul 2015

(Continued)
Duration: 15 minutes per session.
Clinic administered.

Outcomes

Pain intensity: mean, maximal and minimal pain intensity levels. Brief pain inventory
measured pretreatment and post-treatment
Pain 0-10 cm VAS.
Outcomes measured at baseline, pretreatment and post-treatment each treatment session/
treatment modality
Study reported adverse events and none occurred.

Notes

No carry-over tests reported. No baseline comparisons between groups reported. No
conflict of interest stated

Risk of bias
Bias

Authors’ judgement

Support for judgement

Random sequence generation (selection Low risk
bias)

Table of random numbers.

Allocation concealment (selection bias)

Cross-over.

Low risk

Blinding of participants and personnel Unclear risk
(performance bias)
All outcomes

Both active non-invasive treatments.

Blinding of outcome assessment (detection Unclear risk
bias)
All outcomes

As above.

Incomplete outcome data (attrition bias)
All outcomes

Dropout from study described and minimal.

Low risk

Incomplete outcome data (participant ex- Low risk
clusion from analysis)

Appears adequate.

Selective reporting (reporting bias)

Low risk

Adequately reported.

Other bias

Unclear risk

No formal assessment of carry-over effects but data
appeared very similar at baseline

Size of study

High risk

n = 12 per group.

µs: microseconds; ACU: electroacupuncture; DN4: Douleur Neuropathique 4; DPN: diabetic peripheral neuropathy; IFT: interferential
therapy; LANSS: Leeds Assessment of Neuropathic Symptoms and Signs; n: sample size; NRS: numerical rating scale; NSAID: nonsteroidal anti-inflammatory drug; PENS: percutaneous electrical nerve stimulation; PRF: pulsed radiofrequency; RCT: randomised
controlled trial; RDQ: Roland-Morris Disability Questionnaire; SD: standard deviation; SF-36: 36-item Short Form; TENS:
transcutaneous electrical nerve stimulation; VAS: visual analogue scale; VI: visual illusion.
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Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Al-Smadi 2003

Not defined neuropathic pain.

Bahtereva 2009

Not a standard TENS unit application. Unable to contact authors

Bloodworth 2004

Not randomised/quasi-randomised trial.

Bourke 1994

Not randomised/quasi-randomised trial.

Casale 1985

Outcome measure not pain intensity.

Cheing 2005

Pain intensity scoring in response to stimulus evoked pain. Stimulus applied by researcher

Chitsaz 2009

Outcome measure a VAS composite of pain and sensory complaints

Connolly 2013

All participants received perceptual TENS.

Finsen 1988

Outcome measure not Pain intensity.

Forst 2004

Outcome measure a VAS composite of pain and sensory symptoms

Franca 2013

Not defined neuropathic pain.

Gossrau 2011

TENS applied below perceptual level.

Heidenreich 1988

Not clearly randomised trial.

Ing 2015

Not a standard TENS device.

Katz 1991

Outcome measured < 24 hours post-treatment.

Kumar 1997

Outcome measure not pain intensity. VAS was a composite of pain intensity, paraesthesia and sleep disturbance.
Outcome measure not self-reported

Kumar 1998

Outcome measure not pain intensity. VAS was a composite of pain intensity, paraesthesia and sleep disturbance.
Outcome measure not self-reported

Lehmkuhl 1978

Outcome measured < 24 hours post-treatment.

Marques 2014

Not defined neuropathic pain.

Mysliwiec 2012

Outcome measure not pain intensity. Not defined neuropathic pain participants

Norrbrink 2009

All participants received TENS.
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(Continued)

Oosterhof 2008

No pain intensity follow-up data. Unable to extract potential neuropathic participant data

Pourmomeny 2009

Outcome measure not pain intensity. VAS was a composite measure of pain and non-pain symptoms

Reichstein 2005

Not all participants had pain as a symptom. Outcome measure encompassed non-pain symptoms

Sherry 2001

Not defined neuropathic pain.

Stepanovic 2015

Not defined neuropathic pain.

Thorsteinsson 1977

Outcome measured < 24 hours post-treatment.

Warke 2004

Not defined neuropathic pain condition in study.

Warke 2006

Not defined neuropathic pain condition in study.

Wong 2016

Not randomised/quasi-randomised trial.

Yameen 2011

All participants received TENS.

TENS: transcutaneous electrical nerve stimulation; VAS: visual analogue scale.

Characteristics of studies awaiting assessment [ordered by study ID]
ICTRPNCT02496351
Methods

Not available.

Participants

Not available.

Interventions

Not available.

Outcomes

Not available.

Notes

Unable to contact study authors.

Samier 2006
Methods
Participants
Interventions
Outcomes
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Samier 2006

Notes

(Continued)

Attempted contact with author. No reply.

Wang 2009
Methods

RCT, parallel

Participants

Randomised n = 139 with ’senile radical sciatica’ randomised to electroacupuncture (n = 70) or TENS (n = 69)
treatments. Awaiting translation. No further details

Interventions

Awaiting translation.

Outcomes
Notes

n: number of participants; TENS: transcutaneous electrical nerve stimulation.
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DATA AND ANALYSES

Comparison 1. TENS versus sham TENS

Outcome or subgroup title

No. of
studies

No. of
participants

5
4

207
174

1 Changes in pain intensity
2 Pain intensity sensitivity analysis
(Celik 2013 removed)

Statistical method

Effect size

Mean Difference (IV, Random, 95% CI)
Mean Difference (IV, Random, 95% CI)

-1.58 [-2.08, -1.09]
-1.44 [-1.87, -1.02]

Analysis 1.1. Comparison 1 TENS versus sham TENS, Outcome 1 Changes in pain intensity.
Review:

Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults

Comparison: 1 TENS versus sham TENS
Outcome: 1 Changes in pain intensity

Study or subgroup

TENS

Mean
Difference

Sham TENS

Weight

N

Mean(SD)

N

Mean(SD)

Barbarisi 2010 (1)

9

2.5 (0.97)

8

3.7 (1.19)

16.5 %

-1.20 [ -2.24, -0.16 ]

Barbarisi 2010 (2)

7

2.3 (0.78)

6

3.2 (0.81)

21.0 %

-0.90 [ -1.77, -0.03 ]

Bi 2015

24

2.14 (0.91)

24

3.87 (1.45)

27.8 %

-1.73 [ -2.41, -1.05 ]

Buchmuller 2012

43

3.85 (2.97)

32

5.78 (1.9)

15.1 %

-1.93 [ -3.04, -0.82 ]

Celik 2013

17

3.88 (2.5)

16

6.77 (1.42)

10.7 %

-2.89 [ -4.27, -1.51 ]

Vitalii 2014

11

3.95 (1.7)

10

5.25 (1.86)

9.0 %

-1.30 [ -2.83, 0.23 ]

100.0 %

-1.58 [ -2.08, -1.09 ]

Total (95% CI)

111

IV,Random,95% CI

Mean
Difference
IV,Random,95% CI

96

Heterogeneity: Tau2 = 0.11; Chi2 = 7.04, df = 5 (P = 0.22); I2 =29%
Test for overall effect: Z = 6.23 (P < 0.00001)
Test for subgroup differences: Not applicable

-4

-2

Favours TENS

0

2

4

Favours sham TENS

(1) P300
(2) P600
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Analysis 1.2. Comparison 1 TENS versus sham TENS, Outcome 2 Pain intensity sensitivity analysis (Celik
2013 removed).
Review:

Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults

Comparison: 1 TENS versus sham TENS
Outcome: 2 Pain intensity sensitivity analysis (Celik 2013 removed)

Study or subgroup

TENS

Mean
Difference

Sham TENS

Mean
Difference

Weight

N

Mean(SD)

N

Mean(SD)

Barbarisi 2010 (1)

7

2.3 (0.78)

6

3.2 (0.81)

23.6 %

-0.90 [ -1.77, -0.03 ]

Barbarisi 2010 (2)

9

2.5 (0.97)

8

3.7 (1.19)

16.4 %

-1.20 [ -2.24, -0.16 ]

Bi 2015

24

2.14 (0.91)

24

3.87 (1.45)

37.9 %

-1.73 [ -2.41, -1.05 ]

Buchmuller 2012

43

3.85 (2.97)

32

5.78 (1.9)

14.5 %

-1.93 [ -3.04, -0.82 ]

Vitalii 2014

11

3.95 (1.7)

10

5.25 (1.86)

7.6 %

-1.30 [ -2.83, 0.23 ]

100.0 %

-1.44 [ -1.87, -1.02 ]

Total (95% CI)

94

IV,Random,95% CI

IV,Random,95% CI

80

Heterogeneity: Tau2 = 0.0; Chi2 = 3.17, df = 4 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 6.71 (P < 0.00001)
Test for subgroup differences: Not applicable

-4

-2

Favours TENS

0

2

4

Favours sham TENS

(1) P600
(2) P300

ADDITIONAL TABLES
Table 1. Details of participants and TENS parameters in included studies

Study, comparison (admitted sample
size)

Group
NeuroReported
Diagnostic
basepathic con- mean dura- criteria
line pain in- dition
tion
tensity
VAS/NRS

Hz
and Electrode
pulse width location

Intensity

Duration, frequency and
site
of administration

Barbarisi
2010
TENS
vs
sham TENS
(30)

P300
Postherpetic
+ TENS: 4 ± neuralgia
0.93
P600
+ TENS: 3.8
0.95
P300
+

100
“Around site
Hz (later de- of pain”
scribed
in text as 50
Hz)
125 µs

“Clear nonpainful
paraesthesia”.
Titrated
to maintain
strength of

30 minutes
daily for 4
weeks
Clinic administration

15.25 ± 8.7 No formal
months
or
clinical neuropathic diagnostic criteria
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(Continued)

sham
TENS: 4.1 ±
1.19
P600
+
sham
TENS: 3.2 ±
0.81

perception

Bi 2015
TENS
vs
sham TENS
(52)

TENS: 5.17 Spinal cord 6.9
±
± 2.34 Sham injury
3.6 months
TENS: 5.56
(since spinal
± 2.07
cord injury)

No formal 2 Hz
or
200 ms
clinical neuropathic diagnostic criteria

Placed “on 50 mA. No
region with description
pain”
of perceived
sensation

20 minutes
3 × weekly
for 12 weeks
Clinic administration

Buchmuller
2012
TENS
vs
sham TENS
(122)

TENS: 6.15
± 2.24 Sham
TENS: 5.91
± 2.12

Clinical as- Mixed: 80sessment
100 Hz alternated
with 2 Hz
200 ms

Placed
on low back
and radicular region of
pain

1 hour. 4 ×
daily for 3
months
Self-administered
at
home

Nerve con- 100 Hz
duction
80 ms
study

Over carpal “Below
30 minutes
ligament
muscle con- 5 × weekly
and median traction”
for 3 weeks
nerve
Clinic administration

LumNot
bar radicular reported
pain (subgroup data
supplied by
authors)

Casale 2013 TENS:
6 Carpal tun- Not
TENS
vs ± 0.8 Laser?: nel
reported
laser? (20)
6.6 ± 1.1
syndrome

Celik 2013
TENS
vs
sham TENS
(33)

TENS: 5.79 Spinal cord 19.1 months LANSSa
± 2.17
injury
12
Sham
TENS: 5.64
± 1.81

Gerson
TENS: 27.0 Postherpetic
1977
Drug: 59.0 neuralgia
TENS
vs (0-100)
drug
treatment
(29)
Ghoname
1999
TENS
vs
PENS (64)

No details

TENS: 7.0 ± Lum21 ±
1.9
bar radicular months
PENS: 7.2 ± pain
1.8
Sham
PENS: 6.6 ±
1.9

> 4 Hz
200 µs

No formal No details
or
clinical neuropathic diagnostic criteria
9 Clinical as- 4 Hz
sessment.
100 ms
Radiological
assessment
of nerve root
compression
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Low intensity paraesthesia alternated with
high intensity (muscle
twitches)

Placed “on 50 mA. No
region with description
pain”
of perceived
sensation

30 minutes
1 × daily for
10 days
Clinic administration

“Placed on No detail
affected dermatome”

15
minutes 1 ×
weekly for 4
weeks then 1
× fortnightly
for 3 weeks

Placed
“Highon posterior est tolerable
lower limb
sensation” without muscle
twitch

30 minutes
3 × weekly
for 3 weeks
Clinic administration
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(Continued)

Koca 2014
TENS: 8.06 Carpal tun- 13.3 ± 6.3 Nerve con- 100 Hz
nel
months
duction
80 ms
TENS
vs ± 0.55
IFT: 8.25 ± syndrome
study
IFT (75)
0.4
Splint: 8.31
± 0.6

Placed on No details
“palmar aspect
of
hand/wrist”

Nabi 2015
TENS
vs PRF sympathectomy
(65)

TENS: 6.10 PeriphPRF sympa- eral diabetic
thectomy: 6. neuropathy
46
(NRS)

“Around
“two
to 20 minutes
shin and an- three times 10
treatkle”
sensory
ment sesthreshold”
sions on alternate days
Clinic administration

zkul 2015
TENS vs visual illusion
(26)

TENS: 5.33 Spinal cord 12.4 ± 17.8 ≥ 4 on DN4 80 Hz
± 1.20
injury
months
180 µs
Visual
illusion:
5.33 ± 1.37

12.9 ± 3 Clinical di- 80 Hz
years (since agnosis
200 µs
diabetes
onset)

Prabhakar
Not stated
2011
TENS
vs
cervical
spine mobilisation (75)

CerNo details
vical radicular pain (75)

Rutgers
Not stated
1988
TENS
vs acupuncture (26)

Postherpetic
neuralgia

Serry 2015
Not stated
TENS vs exercise
(60)

Periph12.2 ± 2.3
eral diabetic years
neuropathy (since onset
of neuropathy
)

No formal 100 Hz
or
50 µs
clinical neuropathic diagnostic criteria

“3 months No formal 100 Hz
to 9 years”
or
200 µs
clinical neuropathic diagnostic criteria

No formal 15 Hz
or
250 µs
clinical neuropathic diagnostic criteria
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20 minutes
5 × weekly
for 3 weeks
Clinic administration

Bilater“perceptially around ble but comspine above fortable”
level of injury

30 minutes
5 × weekly
for 2 weeks
Clinic administration

Placed
at No details
’cervical spinal
segment and
distal
dermatome

30 minutes
10 sessions
on alternate
days over 3
weeks
Clinic administration

“Ei“Fairly
3
ther side of strong sen- × 30 minute
painful area” sation”
clinic sessions week
1.
Then
home use for
5 weeks. No
detail
on home use
frequency/
duration
Lower
ankle

leg/ “Strong
rhythmic
muscle contractions”

30 minutes
3 × weekly
for 8 weeks
Clinic administration
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13
± 1.5 days
(since onset
of phantom
limb pain)

(Continued)

Tilak 2016
TENS
vs
mirror therapy

TENS: 5.00 Phantom
± 1.63
limb pain
Mirror: 5.46
± 1.67

No formal No details
or
clinical neuropathic diagnostic criteria

Vitalii 2014
TENS
vs
sham TENS
(25)

TENS: 8.09 Spinal cord 12.7 months LANSS > 12 4 Hz
± 0.97
injury
200 ms
Sham
TENS: 8.05
± 1.05

Site of pain “Strong but 20 minutes
contralateral comfort1 × daily for
limb
able”
4 days
Clinic administration

Proximal
50 mA. No
and distal to description
pain region of perceived
sensation

30 minutes
1 × daily for
10 days
Clinic administration

DN4: Douleur Neuropathique 4; IFT: interferential therapy; LANSS: Leeds Assessment of Neuropathic Symptoms and Signs pain scale;
NRS: numerical rating scale; P300: pregabalin 300 mg; P600: pregabalin 600 mg; PENS: percutaneous electrical nerve stimulation;
PRF: pulsed radiofrequency; TENS: transcutaneous electrical nerve stimulation; VAS: visual analogue scale.

APPENDICES
Appendix 1. Search strategies
CENTRAL
#1 MESH DESCRIPTOR Transcutaneous Electric Nerve Stimulation EXPLODE ALL TREES
#2 (“TENS” or “TNS” or “ENS” or “TES”):TI,AB,KY
#3 ((“transcutaneous electric nerve stimulation” or “transcutaneous electrical nerve stimulation” or “transcutaneous nerve stimulation”)):
TI,AB,KY
#4 ((“electric nerve stimulation” or “electrical nerve stimulation” or “electrostimulation therap*” or “electro-stimulation therap*”)):
TI,AB,KY
#5 ((“electric nerve therap*” or “electrical nerve therap*” or electroanalgesi*)):TI,AB,KY
#6 ( (“transcutaneous electric stimulation” or “transcutaneous electrical stimulation”)):TI,AB,KY
#7 #1 OR #2 OR #3 OR #4 OR #5 OR #6
#8 MESH DESCRIPTOR PAIN EXPLODE ALL TREES
#9 MESH DESCRIPTOR Peripheral Nervous System Diseases EXPLODE ALL TREES
#10 MESH DESCRIPTOR SOMATOSENSORY DISORDERS EXPLODE ALL TREES
#11 (((pain* or discomfor*) adj10 (central or complex or rheumat* or muscl* or nerv* or neuralgia* or neuropath*))):TI,AB,KY
#12 (((neur* or nerv*) adj6 (compress* or damag*))):TI,AB,KY
#13 #8 OR #9 OR #10 OR #11 OR #12
#14 #7 AND #13
MEDLINE
1 exp Transcutaneous Electric Nerve Stimulation/
2 (“TENS” or “TNS” or “ENS”).ti.
3 (“TENS” or “TNS” or “ENS”).ab.
4 (“transcutaneous electric$ nerve stimulation” or “transcutaneous nerve stimulation”).mp.
5 (“electric$ nerve stimulation” or “electrostimulation therap$” or “electro-stimulation therap$”).mp.
6 (“electric$ nerve therap$” or electroanalgesi$).mp.
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7 transcutaneous electric$ stimulation.mp.
8 TES.ti,ab.
9 or/1-8
10 exp PAIN/
11 exp PERIPHERAL NERVOUS SYSTEM DISORDERS/
12 exp SOMATOSENSORY DISORDERS/
13 ((pain* or discomfor*) adj10 (central or complex or rheumat* or muscl* or nerv* or neuralgia* or neuropath*)).tw.
14 ((neur* or nerv*) adj6 (compress* or damag*)).tw.
15 10 or 11 or 12 or 13 or 14
16 9 and 15
17 randomized controlled trial.pt.
18 controlled clinical trial.pt.
19 randomized.ab.
20 placebo.ab.
21 drug therapy.fs.
22 randomly.ab.
23 trial.ab.
24 groups.ab.
25 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
26 exp animals/ not humans.sh.
27 25 not 26
28 16 and 27
Embase
1. exp Transcutaneous Electric Nerve Stimulation/
2. (“TENS” or “TNS” or “ENS”).ti.
3. (“TENS” or “TNS” or “ENS”).ab.
4. (“transcutaneous electric nerve stimulation” or “transcutaneous electrical nerve stimulation” or “transcutaneous nerve stimulation”).tw.
5. (“electric nerve stimulation” or “electrical nerve stimulation” or “electrostimulation therap$” or “electro-stimulation therap$”).tw.
6. (“electric nerve therap$” or “electrical nerve therap$” or electroanalgesi$).tw.
7. (“transcutaneous electric stimulation” or “transcutaneous electrical stimulation”).tw.
8. TES.ti,ab.
9. or/1-8
10. exp PAIN/
11. exp PERIPHERAL NEUROPATHY/
12. exp SOMATOSENSORY DISORDERS/
13. ((pain* or discomfor*) adj10 (central or complex or rheumat* or muscl* or nerv* or neuralgia* or neuropath*)).tw.
14. ((neur* or nerv*) adj6 (compress* or damag*)).tw.
15. 10 or 11 or 12 or 13 or 14
16. 9 and 15
17. random$.tw.
18. factorial$.tw.
19. crossover$.tw.
20. cross over$.tw.
21. cross-over$.tw.
22. placebo$.tw.
23. (doubl$ adj blind$).tw.
24. (singl$ adj blind$).tw.
25. assign$.tw.
26. allocat$.tw.
27. volunteer$.tw.
28. Crossover Procedure/
29. double-blind procedure.tw.
30. Randomized Controlled Trial/
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31. Single Blind Procedure/
32. or/17-31
33. (animal/ or nonhuman/) not human/
34. 32 not 33
35. 16 and 34
36. limit 35 to embase
PsycINFO
1. exp Transcutaneous Electric Nerve Stimulation/
2. (“TENS” or “TNS” or “ENS”).ti.
3. (“TENS” or “TNS” or “ENS”).ab.
4. (“transcutaneous electric nerve stimulation” or “transcutaneous electrical nerve stimulation” or “transcutaneous nerve stimulation”).tw.
5. (“electric nerve stimulation” or “electrical nerve stimulation” or “electrostimulation therap$” or “electro-stimulation therap$”).tw.
6. (“electric nerve therap$” or “electrical nerve therap$” or electroanalgesi$).tw.
7. (“transcutaneous electric stimulation” or “transcutaneous electrical stimulation”).tw.
8. TES.ti,ab.
9. or/1-8
10. exp PAIN/
11. exp PERIPHERAL NEUROPATHY/
12. exp SOMATOSENSORY DISORDERS/
13. ((pain* or discomfor*) adj10 (central or complex or rheumat* or muscl* or nerv* or neuralgia* or neuropath*)).tw.
14. ((neur* or nerv*) adj6 (compress* or damag*)).tw.
15. 10 or 11 or 12 or 13 or 14
16. 9 and 15
17. clinical trials/
18. (randomis* or randomiz*).tw.
19. (random$ adj3 (allocat$ or assign$)).tw.
20. ((clinic$ or control$) adj trial$).tw.
21. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
22. (crossover$ or “cross over$”).tw.
23. random sampling/
24. Experiment Controls/
25. Placebo/
26. placebo$.tw.
27. exp program evaluation/
28. treatment effectiveness evaluation/
29. ((effectiveness or evaluat$) adj3 (stud$ or research$)).tw.
30. or/17-29
31. 16 and 30
AMED
1. exp Transcutaneous Electric Nerve Stimulation/
2. (“TENS” or “TNS” or “ENS”).ti.
3. (“TENS” or “TNS” or “ENS”).ab.
4. (“transcutaneous electric nerve stimulation” or “transcutaneous electrical nerve stimulation” or “transcutaneous nerve stimulation”).tw.
5. (“electric nerve stimulation” or “electrical nerve stimulation” or “electrostimulation therap$” or “electro-stimulation therap$”).tw.
6. (“electric nerve therap$” or “electrical nerve therap$” or electroanalgesi$).tw.
7. (“transcutaneous electric stimulation” or “transcutaneous electrical stimulation”).tw.
8. TES.ti,ab.
9. or/1-8
10. exp PAIN/
11. exp PERIPHERAL Nervous system disease/
12. ((pain* or discomfor*) adj10 (central or complex or rheumat* or muscl* or nerv* or neuralgia* or neuropath*)).tw.
13. ((neur* or nerv*) adj6 (compress* or damag*)).tw.
14. 10 or 11 or 12 or 13
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15. 9 and 14
16. randomized controlled trials/
17. randomized controlled trial.pt.
18. controlled clinical trial.pt.
19. placebo.ab.
20. random*.ti,ab.
21. trial.ti,ab.
22. groups.ab.
23. 16 or 17 or 18 or 19 or 20 or 21 or 22
24. 15 and 23
CINAHL
S26 S16 AND S25
S25 S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24
S24 (allocat* random*)
S23 (MH “Quantitative Studies”)
S22 (MH “Placebos”)
S21 placebo*
S20 (random* allocat*)
S19 (MH “Random Assignment”)
S18 (Randomi?ed control* trial*)
S17 (singl* blind* ) or (doubl* blind* ) or (tripl* blind* ) or (trebl* blind* ) or (trebl* mask* ) or (tripl* mask* ) or (doubl* mask* ) or
(singl* mask* )
S16 S9 AND S15
S15 S10 OR S11 OR S12 OR S13 OR S14
S14 ((neur* or nerv*) N6 (compress* or damag*)).
S13 ((pain* or discomfor*) N10 (central or complex or rheumat* or muscl* or nerv* or neuralgia* or neuropath*)).
S12 (MH “Somatosensory Disorders+”)
S11 (MH “Peripheral Nervous System Diseases+”)
S10 (MH “Pain+”)
S9 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8
S8 TES
S7 (“transcutaneous electric stimulation” or “transcutaneous electrical stimulation”).
S6 (“electric nerve therap*” or “electrical nerve therap*” or electroanalgesi*)
S5 “electric nerve stimulation” or “electrical nerve stimulation” or “electrostimulation therap*” or “electro-stimulation therap*”).
S4 (“transcutaneous electric nerve stimulation” or “transcutaneous electrical nerve stimulation” or “transcutaneous nerve stimulation”)
S3 (“electric nerve stimulation” or “electrical nerve stimulation” or “electrostimulation therap*” or “electro-stimulation therap*”).
S2 (“TENS” or “TNS” or “ENS”).
S1 (MH “Transcutaneous Electric Nerve Stimulation”)
Web of Science
#17 #16 AND #10
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#16 #15 AND #14
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#15 TOPIC: (human*)
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#14 #13 OR #12 OR #11
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#13 TOPIC: (((((singl* OR doubl* OR trebl* OR tripl*) SAME (blind* OR mask*)))))
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#12 TOPIC: ((((controlled clinical trial OR controlled trial OR clinical trial OR placebo))))
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#11 TOPIC: ((((randomised OR randomized OR randomly OR random order OR random sequence OR random allocation OR
randomly allocated OR at random OR randomized controlled trial))))
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Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#10 #9 AND #6
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#9 #8 OR #7
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#8 TOPIC: (((neur* or nerv*) Near/6 (compress* or damag*)).)
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#7 TOPIC: (((pain* or discomfor*) near/10 (central or complex or rheumat* or muscl* or nerv* or neuralgia* or neuropath*)).)
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#6 #5 OR #4 OR #3 OR #2 OR #1
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#5 TOPIC: ((“transcutaneous electric stimulation” or “transcutaneous electrical stimulation”))
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#4 TOPIC: ((“electric nerve therap*” or “electrical nerve therap*” or electroanalgesi*))
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#3 TOPIC: ((“transcutaneous electric nerve stimulation” or “transcutaneous electrical nerve stimulation” or “transcutaneous nerve
stimulation”))
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#2 TOPIC: ((“electric nerve stimulation” or “electrical nerve stimulation” or “electrostimulation therap*” or “electro-stimulation
therap*”).)
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
#1 TOPIC: ((“TENS” or “TNS” or “ENS” or “TES”))
Indexes=SCI-EXPANDED, SSCI, CPCI-S, CPCI-SSH Timespan=All years
LILACS
TENS or TNS or ENS or transcutaneous or TES or nerve stimulation or electrostimulat$ [Words] and pain$ or discomfor$ or
compress$ or damag$ [Words] and random$ or trial$ or crossover$ or blind$ or placebo$ [Words]

Appendix 2. Included study methodology description
Pooled studies
Barbarisi 2010 (n = 30) used a two arm parallel design in participants with post-herpetic neuralgia PHN). All participants undertook
an initial eight day programme of pregabalin drug treatment at varying doses with the aim of reducing all participants baseline visual
analogue scale (VAS) pain intensity scores to 60 mm or less on a 0 to 100 mm VAS scale. There was no information with regard to how
many participants were initially enrolled in the drug titration phase. Following this, 30 drug treatment responders were randomised
to either transcutaneous electrical nerve stimulation (TENS) or sham TENS applied for 30 minutes per day (clinic administered) for
four weeks. Baseline pain intensity post drug titration phase was compared to final pain intensity scores at four weeks. VAS scores of
pain intensity appeared to reflect ’current’ pain intensity. Analysis of participants was subdivided according to the concomitant dose of
pregabalin taken during the study. The comparison was: pregabalin 300 mg plus TENS versus pregabalin 300 mg plus sham TENS,
pregabalin 600 mg plus TENS versus pregabalin 600 mg plus sham TENS.
Bi 2015 randomised 52 participants with spinal cord injury into TENS versus sham TENS groups. Pain intensity was assessed (on
a 0 to 10 VAS) at baseline and then immediately upon cessation of 12 weeks of treatment. The VAS reflected current pain intensity
at time of measurement. Participants were treated three times per week for 12 weeks and the TENS/sham TENS was administered
in the treating clinic. Celik 2013 carried out a similar sized study in 33 participants with spinal cord injury randomised to TENS or
sham TENS. Daily treatment of 30 minute duration was administered in the clinic. Pain intensity VAS scores (on a 0 to 10 VAS) were
recorded morning, noon, evening and night pretreatment and post-treatment; day one of the protocol consisted of these four VAS
assessments. Participants then had 10 days of treatment intervention. Day 12 of the protocol consisted of assessing the pain intensity
with the same four VAS measures used at day one. Means of the four measures obtained at day one and day 12 were calculated and
used in the final analysis. It is worth noting that both groups were also taking amitriptyline 10 mg as a concomitant treatment in this
study. Vitalii 2014 used a similar methodology with participants who had spinal cord injury. Participants were randomised to TENS
or sham TENS groups and then received 30 minute clinic administered treatment daily for 10 days. This study employed concomitant
treatment with gabapentin 900 mg. Pain intensity (0 to 10 VAS) scores were a mean of morning and evening reporting. Data were
reported as ’day zero’ baseline and post-treatment ’day 10’ scores.
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Buchmuller 2012 randomised 236 participants with chronic low back pain into two groups receiving either TENS or sham TENS. As a
subgroup within this sample, 139 participants were classified as having a neuropathic component to their condition. This classification
was made on the basis of clinical assessment. The primary outcome of this study was functional change assessed via the Roland-Morris
Disability Questionnaire (RDQ). Secondary outcomes included dichotomising participants according to pain intensity changes (50%
decrease in on a 0 to 10 VAS classed as criteria for improvement) from baseline to post-treatment. While the paper reported the data in
this dichotomised method, following contact the authors were able to provide pain intensity data for participants from the neuropathic
group and specifically for those participants with a radicular pain component. These pain intensity data were used when pooling data.
Radicular pain was assessed in 122 participants at baseline and then reassessed at three months. In the active TENS group at baseline
there were data for 64 participants while in the sham TENS group baseline data were available for 58 participants. Following completion
of treatment and with dropout there were data for 43 participants in the active TENS group and 32 participants in the sham TENS
group. The TENS/sham TENS units were supplied to the participant for home administration. Participants were instructed to compete
four TENS session per day with each session lasting one hour.
Narrative review single studies
Casale 2013 compared laser with TENS for pain intensity (on a 0 to 10 VAS) and paraesthesia in 20 participants with carpal tunnel
syndrome. Treatments were applied five times per week for five weeks. Treatment duration was 30 minutes for TENS. Treatment
duration for laser application was unclear. There was no information given with respect to the pain intensity VAS measure (mean pain,
peak pain, etc.) and timing of assessment was only described as being “evaluated before and after treatment.”
Gerson 1977 compared pharmacological treatment (carbamazepine plus clomipramine) versus TENS in 29 participants with postherpetic neuralgia. There were no reported parameters around TENS application beyond stating the duration of treatment was 15
minutes per session. It appears the TENS group initially received four treatments on a weekly basis followed by three TENS sessions at
fortnightly intervals (seven TENS sessions in total). This equated to a 10 week treatment period; however, the drug treatment group
was reported as being eight weeks in duration and outcomes are reported at eight weeks. Pain intensity (on a 0 to 100 mm VAS) was
assessed at initially weekly then fortnightly intervals via a VAS; however, it was not stated whether this was current pain, mean pain or
maximal pain.
Ghoname 1999 in a one-arm randomised cross-over study compared percutaneous electrical nerve stimulation (PENS) versus TENS
versus sham PENS in participants with lumbar radicular pain. However, the sham treatment was invasive, involving insertion of
“acupuncture like needles” into the involved area. We considered this to be very problematic as a sham intervention and therefore
only considered the TENS versus PENS comparison. The main comparison involved a non-invasive intervention (TENS) being
compared against an inherently invasive procedure (PENS), therefore this study rated high risk across the key domains of participant/
personnel bias. Sixty-four participants were randomised to three different treatment sequences 1. sham PENS, PENS, TENS; 2. PENS,
TENS, sham PENS; 3. TENS, sham PENS, PENS. Each treatment phase lasted three weeks with a one week washout break between.
Participants received three treatment sessions per week (clinic administered) of 30 minutes’ duration. Pain intensity data (0 to 10 VAS)
were reported and analysed during treatment and at 24 hours post treatment phase completion.
One three arm study compared TENS, interferential (IFT) and resting splints in participants with carpal tunnel syndrome (Koca 2014).
This study randomised 75 participants to one of three treatment groups. Pain intensity was assessed (on a 0 to 10 VAS) as a mean of
the previous week’s pain at baseline and three weeks after completion of treatment. The splint group were instructed to use resting
wrist-hand night splints during the intervention period. The TENS and IFT therapies were delivered in the clinic five times per week
for 20 minutes each session.
Nabi 2015 investigated TENS versus pulsed radiofrequency (PRF) sympathectomy in 65 participants with painful peripheral diabetic
neuropathy of the lower limb. Participants were randomised to either PRF sympathectomy or TENS interventions and both groups
received concomitant treatment with pregabalin 300 mg/day to 600 mg/day. The main comparison involved a non-invasive intervention
(TENS) being compared against an inherently invasive procedure (PRF sympathectomy), therefore this study rated high risk across the
key domains of participant/personnel bias. Participants assigned to the PRF sympathectomy group initially underwent a sympathetic
blockade with local anaesthetic. Participants who reported a 50% reduction in pain then progressed to PRF sympathectomy. There
were no data on how many participants underwent the initial local anaesthetic procedure or how many of this group went on to full
PRF sympathectomy. Participants in the both groups had pain intensity (0-10 numerical rating scale (NRS)) assessed four times before
the procedure (PRF sympathectomy or TENS treatment to completion) and then at one week, one month and three months after
completion of the procedure. It was unclear if NRS scores at baseline were a mean of the four preintervention assessments or whether
the NRS elicited at each assessment represented current pain, maximal pain or mean pain. The PRF sympathectomy intervention was
a one-off single day procedure whereas the TENS was delivered as 10 × 20 minute sessions delivered on alternate days. Given the NRS
assessments were completed at fixed times post ’procedure’ and completion of the TENS treatment was regarded as a procedure, there
was an imbalance in outcome assessment timing postrandomisation for the two groups (TENS assessments approximately three weeks
later than PRF sympathectomy).
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One study investigated TENS versus visual illusion in participants with neuropathic pain following spinal cord injury ( zkul 2015).
This two-arm randomised cross-over study allocated 24 participants to groups and received the following intervention sequences:
Group one (12 participants) received visual illusion then TENS and Group two (12 participants) received TENS followed by visual
illusion. Treatments were delivered five times per week over two weeks followed by one week washout between treatments. TENS
sessions lasted 30 minutes while virtual illusion sessions lasted 15 minutes. This study was rated overall unclear in terms of bias and
was not allocated high risk of bias in any domain. Pain intensity data (0 to 10 VAS) was reported at baseline and immediately upon
completion of treatment (two weeks). Group mean pain intensity data were presented across the combined groups preintervention
and postintervention. Carry-over testing prior to initiation of second sequence treatment was not reported. Pain intensity reported as
present pain (immediately upon cessation of treatment), mean (timeframe not described), minimal and maximal at baseline and posttreatment.
Prabhakar 2011 investigated TENS versus cervical mobilisation versus isometric exercises in participants with cervical radiculopathy.
This randomised parallel design allocated 75 participants to one of these three interventions. The number of participants per group
was not described. All participants initially received hot pack therapy and treatment interventions were applied on alternate days for
10 sessions over three weeks. TENS sessions lasted approximately 30 minutes. There were no details on duration of treatment in the
mobilisation or isometric exercise group. Pain intensity (VAS not specified) was assessed at baseline then at three weeks (completion
of treatment) and six weeks (three weeks after treatment completed). The parameters of the VAS pain intensity measure (e.g. mean,
minimal, maximal pain) were not described.
One study investigated acupuncture (ACU, 10 participants) and TENS (13 participants) in people with postherpetic neuralgia (Rutgers
1988). All treatment interventions lasted six weeks. The ACU group were treated twice per week for six weeks with body and auricular
acupuncture while the TENS group received 3 × 30 minute TENS sessions in the first week (clinic administered) and were then
instructed to apply TENS themselves at home for the next five weeks. There were no details on TENS duration, dosage or treatment
parameters for the home treatment component of the intervention. Pain intensity was assessed via a 10-point stepwise scale. There was
no further detail provided for this scale. Pain intensity was assessed at baseline, six weeks, nine weeks and six months postrandomisation.
This study was rated overall at high risk of bias with the key domains blinding of participants and personnel, incomplete outcome data
and selective reporting of outcomes being rated high.
Serry 2015 investigated TENS versus exercise in 60 participants with diabetic peripheral neuropathy randomised to TENS, exercise
or regular pharmacological therapy groups (20 per group). TENS and exercise groups received treatment three times per week for
eight weeks. TENS sessions lasted 30 minutes, aerobic exercise sessions lasted in total 50 minutes. All treatments were applied under
supervision. Additionally, participants in the TENS and exercise groups continued with concomitant treatment of their regular pharmacological therapy. This study was rated at overall high risk of bias with particular risk in the ’selective reporting of outcome’ domain.
In this study, pain intensity was assessed at baseline and post-treatment on a 0 to 10 VAS although it was unclear what aspect of the
pain experience was assessed (e.g. mean, minimal, maximal pain, etc.).
We include one study investigating TENS versus mirror therapy in participants with phantom limb pain (Tilak 2016). In this study, 26
participants (88% men) were randomised to either TENS (n = 13) or mirror (n = 13) intervention groups. Pain intensity was assessed
with a 0 to 10 VAS and a ’Universal Pain Score’ (participants selects from a range of hand-drawn faces depicting pain expressions
which face most closely matches their experience). It was unclear what aspect of the pain experience was assessed (e.g. mean, minimal,
maximal pain, etc.). Treatments were applied daily for four days. Each treatment session lasted 20 minutes. Baseline demographics
and site of amputation were well described and no significant differences in age, duration of phantom limb pain or pain intensity was
found. Overall, this study was rated unclear on risk of bias with the only domain assessed as high being sample size.
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DIFFERENCES BETWEEN PROTOCOL AND REVIEW
The protocol of this review contained an error that was overlooked in the review process. In the review, we made the following statement
in the ’Assessment of Heterogeneity’ section: “We will attempt to deal with clinical heterogeneity by combining studies that examine
similar conditions because placebo response rates with the same outcome can vary between conditions, as can the treatment specific
effects.”
Following this in the ’Data Synthesis’ section we made this statement: “We will pool data from studies of neuropathic pain regardless
of the specific diagnosis. We will pool data for adverse events across conditions.”
These are conflicting and incompatible. This was done in error and has now been corrected.
The protocol of this review outlined the criteria involved in grading the quality of evidence according to the GRADE approach.
However, we did not explicitly mention that individual criteria may be double downgraded if there were sufficient reasons to do so. In
this review, we downgraded twice on “Limitations of studies” due to sample sizes and multiple high risk of bias issues across at least
four of the five studies included in the pooled analysis.
In the protocol of this review, we stated that we planned to investigate the following comparisons: TENS versus sham TENS, TENS
versus usual care, TENS versus no treatment and TENS in addition to usual care versus usual care alone. We were only able to perform
a quantitative synthesis for the comparison of TENS versus sham TENS. No studies investigated TENS versus no treatment and
TENS in addition to usual care versus usual care alone. The studies investigating TENS versus usual care employed a wide range of
comparative treatments which precluded pooling of data. For the sake of completeness of the evidence, we therefore included a series
of individual narrative reviews of studies investigating TENS versus these other active treatments.

Transcutaneous electrical nerve stimulation (TENS) for neuropathic pain in adults (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

